Posted on

Powdery Mildew — What Every Cannabis Grower Needs to Understand

Two 2025 studies reveal how powdery mildew infects cannabis, why some genetics resist it, and how to fight the fungus without wrecking your living soil.
Powdery Mildew — What Every Cannabis Grower Needs to Understand | The Certified
Grower Fundamentals · Disease Management

We spent last week on rosemary oil and spider mites. This week we're anchoring on the disease every cannabis grower meets sooner or later: powdery mildew. Two 2025 studies — one unpacking the biology of the disease itself, one mapping the first known cannabis-specific resistance gene — give us a real foundation, and they connect straight back to the Korean Natural Farming and FPJ/FFJ ground we've already covered.

Plant Pathology · Cannabis Genetics · Biocontrol

Powdery Mildew — What Every Cannabis Grower Needs to Understand

It's the white dust every grower dreads, and almost everyone gets it eventually. Two 2025 papers — a comprehensive review of powdery mildew biology and a cannabis-specific genetic study — lay out exactly how this fungus invades, why some genetics fight it off, and why the smartest long-term defence looks a lot like the soil biology work you're probably already doing.

The Grower's Connect · · 14 min read
$6.3B estimated annual global economic loss caused by powdery mildew
10,000+ plant species known to be infected by powdery mildew fungi worldwide
70%+ of 510 screened cannabis genotypes showed high susceptibility to PM
90%+ reduction in spore production seen in cannabis with the PM2 resistance gene
Listen to this article Powdery Mildew — What Every Grower Needs to Understand
Audio coming soon — replace this div with your <audio> tag when ready

If you've grown cannabis for more than a season or two, you already know the feeling: a faint dusting of white on a fan leaf that you tell yourself is just pollen or dust, until it isn't. Powdery mildew (PM) is arguably the single most common disease pressure cannabis growers face, indoors or out, and it doesn't discriminate between hobbyists and commercial operations. Globally, powdery mildew fungi are estimated to cause over six billion dollars in agricultural losses every year, across more than ten thousand plant species. In cannabis specifically, it's now understood to be the most prevalent fungal disease in indoor growing operations.

This week we're anchoring on PM properly — not just how to spot it, but how it actually works, why some cannabis genetics fight it off almost entirely while others fold immediately, and why the long-term answer looks less like reaching for a stronger fungicide and more like the soil and microbial work this series keeps circling back to.

How the Infection Actually Happens

Powdery mildew isn't one single organism — it's a large group of related fungi, and the species specifically responsible for most cannabis infections is Golovinomyces ambrosiae (previously classified as G. cichoracearum). Unlike many fungal pathogens, PM is an obligate biotroph — it can only survive on living plant tissue, which is part of why it spreads so readily between plants in a shared grow space.

The infection follows a fairly predictable sequence. A spore lands on a leaf surface and germinates, forming a specialised structure called an appressorium that physically and enzymatically breaches the plant's outer cell wall. Once inside, the fungus develops haustoria — feeding structures that tap directly into host cells to draw out nutrients — while a visible mycelial network spreads across the leaf surface. Within one to two weeks under favourable conditions, the fungus completes its cycle by producing conidiophores, the spore-generating structures responsible for that unmistakable powdery white coating, which then release fresh spores to start the cycle again on neighbouring tissue.

The Conditions That Let It Take Hold

PM favours a fairly specific environmental window, and this is where a grower has the most day-to-day control. High humidity and surface moisture strongly favour spore germination, while poor airflow and dense, heavily shaded canopy create exactly the still, humid micro-climate the fungus wants. Interestingly, PM doesn't need standing water on the leaf the way many other fungal diseases do — elevated humidity alone is often enough.

Conditions That Favour PM

High humidity, poor air circulation, dense or heavily shaded canopy, moderate temperatures, and young, actively growing tissue that hasn't fully hardened off its defences yet.

Conditions That Limit It

Good airflow through the canopy, lower relative humidity, adequate light penetration, and well-nourished plants with a fully induced natural defence response.

Plant nutrition plays a bigger role here than growers often credit. A well-nourished plant mounts a stronger, faster defence response, largely through hormonal signalling — salicylic acid (SA) pathways are central to a plant's fight against biotrophic pathogens like PM, while a separate jasmonic acid/ethylene pathway handles necrotrophic threats. This is precisely why the soil-first approach we keep returning to in this series isn't just about yield — a plant that's genuinely well fed from the root up is measurably better equipped to resist infection in the first place.

Not All Cannabis Is Equally Vulnerable

Here's where things get genuinely exciting for the future of cannabis breeding. Researchers at Aurora Cannabis screened 510 genotypes from their germplasm collection for PM susceptibility, and the results were sobering: more than 70% scored a "disease index" above 50, indicating high susceptibility across the board. But buried in that same population were rare genotypes that resisted infection almost entirely — and the researchers were able to trace that resistance to its genetic source.

Using a technique called bulked-segregant RNA sequencing, they identified a single dominant resistance gene — named PM2 — located on chromosome 9. Plants carrying PM2 didn't just get a little less sick; under microscopy, infected leaves showed a highly localised burst of reactive oxygen species (hydrogen peroxide) right at the point of fungal attack, triggering a hypersensitive response that kills off a tiny patch of the plant's own cells before the fungus can establish itself. The pathogen still lands and tries to penetrate — it just can't get anywhere.

"The plant sacrifices a handful of its own cells at the exact point of attack, and that's enough to stop the fungus from ever completing its life cycle."

The practical outcome was dramatic: genotypes carrying PM2 showed more than a 90% reduction in spore (conidia) production compared to susceptible plants — from an average of over 118 conidiophores per leaf sample down to roughly 5. That's the difference between a plant that shrugs off exposure and one that becomes a spreading source of infection for everything around it.

Why the Industry Is Moving Away from Fungicides Alone

For decades, powdery mildew control has leaned on two tools: resistant cultivars where available, and chemical fungicides everywhere else. But broad chemical use comes with real costs — it drives fungicide-resistant pathogen strains, harms beneficial insects and pollinators, and, critically for growers who've been following this series, degrades the very soil and leaf-surface microbial communities that would otherwise help fight the disease for you.

This is where the research points somewhere genuinely useful: biological control using synergistic combinations of beneficial microbes, particularly Bacillus and Trichoderma species, which compete with PM for space and resources on the leaf surface and can actively trigger the plant's own induced immunity, all while reducing reliance on fungicide.

You Already Have the Tools

Yes, the PM2 genetic resistance gene is incredibly exciting for the future of cannabis breeding, but you don't need to wait for commercial breeders to drop PM2 seed packs to win this fight today. The fundamental biology of Golovinomyces ambrosiae is universally understood: it is a weak pathogen that exploits poor environments and biological vacuums. If you are applying the core principles of regenerative cultivation—building thriving soil biology, feeding the plant through organic inputs rather than salt shocks, brewing your own indigenous microbes, and maintaining tight control over your canopy airflow—you are actively destroying the conditions powdery mildew needs to survive.

You aren't helpless against this fungus, and you don't need to rely solely on chemical fungicides that wreck the rest of your garden's ecology. Your proactive, day-to-day garden management is already your strongest defense. Powdery mildew is a battle fought on multiple fronts—environment, plant nutrition, and microbial ecology—and the growers who treat it that way are the ones who keep it from ever becoming a problem in the first place.

Powdery mildew biology, colonisation, and biocontrol review: Gan, C.-M.; Tang, T.; Zhang, Z.-Y.; Li, M.; Zhao, X.-Q.; Li, S.-Y.; Yan, Y.-W.; Chen, M.-X.; Zhou, X. Unraveling the Intricacies of Powdery Mildew: Insights into Colonization, Plant Defense Mechanisms, and Future Strategies. International Journal of Molecular Sciences 2025, 26, 3513.
Cannabis-specific PM2 resistance gene mapping: Seifi, S.; Leckie, K. M.; Giles, I.; O'Brien, T.; MacKenzie, J. O.; Todesco, M.; Rieseberg, L. H.; Baute, G. J.; Celedon, J. M. Mapping and Characterization of a Novel Powdery Mildew Resistance Locus (PM2) in Cannabis sativa L. Frontiers in Plant Science 2025, 16, 1543229.
Posted on

Grow For the Love of It: Reclaiming Cannabis Culture This Season

Eight years after the ConCourt ruling, it's time to remember why we started growing in the first place — not to supply anyone, just for the love of the plant.
Grow For the Love of It — Reclaiming Cannabis Culture This Season | The Certified
Culture · Community

We've spent this whole run underground — soil biology, root chemistry, rhizosphere bacteria. All useful, all real. But it's almost seed season, and there's a bigger question worth asking before any of that matters: why are you growing at all? This week we put the microscope down and talk about the actual reason most of us started doing this in the first place.

Grower Culture · Home Grow · Seed Season

Grow For the Love of It — Put a Seed in the Ground This Season

It's almost planting time again. Eight years after the Constitutional Court told the state to get out of our gardens, somewhere along the way "growing your own" turned into "running a small business." This season, let's put that down. Grow something because the plant deserves it, and so do you.

The Grower's Connect · · 9 min read
8 years since the Constitutional Court protected your right to grow and use cannabis privately
0 buyers you need lined up before you drop a single seed in the ground this year
2018 the year growing in your backyard just to see what happened was still completely normal
1,854+ strains catalogued on Strainpedia alone — enough reason to pick one just for the name
Listen to this article Grow For the Love of It
Audio coming soon — replace this div with your <audio> tag when ready

Think back to 2018 and 2019, if you were around for it. Someone in your circle had a few pots on a balcony or a corner of the yard they'd half-cleared for the occasion. Nobody was calibrating yield per watt. Nobody was pricing out a harvest before the seed even cracked. You planted something because a mate handed you a cutting, or because you found a pack of seeds in a drawer, or because the ConCourt had just told the whole country that growing your own plant in your own home was, finally, nobody else's business. It was messy, it was experimental, half of it hermied or got eaten by something, and none of that mattered. You were growing because it was fun, because it was yours, and because — after decades of it being illegal to even try — you finally could.

Eight years on, a lot of that spirit has quietly been replaced by spreadsheets. Somewhere between the ruling and now, "I grow cannabis" started needing a follow-up sentence: for who, for how much, is it legit, can you get me some. Home growers started calling themselves cultivators. Cultivators started calling themselves suppliers. And suppliers started feeling like every plant in the garden had a job to do before it was even a seedling. None of that is wrong — there are real growers doing real, serious work, building genuine small businesses out of a plant they love, and that deserves respect. But it became the default expectation for everyone, including the person who just wants a few plants in a pot for themselves. If you grow, apparently, you supply. And if you're not supplying, what's the point?

The Point Was Never the Supply Chain

Here's the reminder this post exists to make: the point was never the supply chain. The 2018 ruling wasn't a business licence. It was the state stepping back and saying an adult growing cannabis for their own private use, in their own home, is a matter of personal freedom — not a crime, and not a commercial application waiting to happen. That's a genuinely rare thing to have won, and it's worth using it exactly as it was intended: to grow something, in your own space, for yourself, because you want to.

"You don't owe anyone a harvest. The plant doesn't care if you're a supplier — it just wants water, light, and someone paying attention."

There is a real, specific joy in growing a plant for no reason beyond wanting to watch it grow. Cannabis rewards that kind of attention more than almost anything else you could put in the ground — it changes visibly week to week, it tells you when it's happy and when it isn't, and by the time you're smoking something you grew from a seed with your own hands, "supply" is the last thing on your mind. That feeling is exactly what got buried under everyone's side hustle, and it's exactly what this season is for reclaiming.

Give Yourself Permission Again

You're allowed to grow one plant and let it be entirely, uselessly, wonderfully just yours. You're allowed to grow a strain because the name made you laugh, or because the breeder's photo looked incredible, or because you smoked it once at a festival in 2019 and never forgot it. You're allowed to grow something and give the whole harvest away to friends instead of selling a gram of it. None of that needs a business case. It needs a pot, some soil, and the seed itself.

Where to Actually Find Something Exciting to Plant

Part of what made 2018/2019 growing so much fun was the sheer novelty of choice — suddenly you could just order seeds and see what showed up. That's still true, arguably more true than ever. Trophy Seeds carries sealed breeder packs from international genetics houses alongside proudly South African classics, so there's real range between old-school landrace-style strains and the newer exotic hybrids everyone's talking about. If you want a wider look at what's trending globally right now, Strainpedia's top strains list tracks reader interest across thousands of cultivars — a genuinely fun rabbit hole if you've got twenty minutes and no plan.

This Season, Just Plant Something

Seed season doesn't wait for you to have a plan. The window is short, the weather's about to turn, and the best time to get something in the ground is before you've talked yourself into needing a reason. So here's your reason, if you need one: because eight years ago the country said you could, because the plant is worth getting to know on its own terms, and because there is nothing quite like the first time a seed you planted with your own hands turns into something you can hold, smell, and share. Go pick something that excites you. Put it in the ground. Let this season be about the plant again.

Seed inspiration browsing: Trophy Seeds — sealed breeder packs and South African classics. Strainpedia's Top Weed Strains — reader-ranked cultivars from around the world.
Legal context: This post reflects the general, publicly known outcome of the 2018 Constitutional Court ruling on private cannabis use and cultivation in South Africa. It's cultural context, not legal advice — speak to a qualified professional for guidance on your own situation.
Posted on

The Web Beneath the Roots — What Actually Happens in Living Soil

ow a mycorrhizal fungus reshapes the bacteria living around a root — and what that means for cannabis living soil.
The Web Beneath the Roots — Going Deeper Into Living Soil | The Certified
Soil Biology · Living Soil

We introduced the soil food web a while back — bacteria, archaea, fungi, protists, nematodes, all of it. Last week we went underground again, straight into the root itself, and found real medicine hiding there. This week we zoom back out one level, to the ground the root actually lives in, and look at a study that captures something living soil growers talk about constantly but rarely see measured: a mycorrhizal fungus walks into a root zone, and the bacterial neighborhood changes because of it.

Soil Biology · Mycorrhizal Fungi · Rhizosphere Ecology

The Web Beneath the Roots — What Actually Happens in Living Soil

"Feed the soil, not the plant" is the mantra. But what does that actually look like at the microbial level? A 1984 grassland study tracked exactly what happens to the bacteria living around a root once a mycorrhizal fungus moves in — and the answer is more interesting, and more specific, than "everything grows more."

The Grower's Connect · · 13 min read
5 groups bacteria, archaea, fungi, protists, and nematodes make up the core cast of the soil food web
5.5% maximum root length the mycorrhizal fungus colonized — still enough to shift the bacteria around it
3 of 5 comparison methods where mycorrhizal colonization significantly boosted one specific rhizosphere bacterium
r = 0.53 correlation between mycorrhizal colonization and that bacterium's population, P = 0.01
Listen to this article The Web Beneath the Roots
Audio coming soon — replace this div with your <audio> tag when ready

Every grower who's committed to living soil already believes something like this: the soil isn't an inert bag of nutrients, it's a community, and the health of your plant depends on the health of that community. It's a good instinct, and it's the whole premise of this series. But "community" is a word that can quietly do a lot of hand-waving. It's easy to nod along with "feed the soil, not the plant" without ever seeing what that community is actually doing to itself, in real numbers, while your roots sit in the middle of it.

That's what makes an old, unglamorous study out of Colorado State University worth pulling back out. It isn't about cannabis, and it isn't recent — it was published in 1984, in a grassland soil, on a grass species most growers have never heard of. But it did something most soil-biology writing doesn't: it isolated one single relationship inside the soil food web — a mycorrhizal fungus and the bacteria living in its immediate neighborhood — and simply measured what happened. No hand-waving. Counted colonies, on plates, compared with statistics. That kind of unglamorous, methodical measurement is exactly what makes the more general "soil food web" story feel less like philosophy and more like biology you can build a growing method around.

A Quick Refresher: Who's Actually Down There

Before going deeper, it's worth restating the cast, because the rest of this piece leans on all of them. The soil food web is built on primary decomposers — bacteria and archaea — that break down organic material and release the nutrients locked inside it. Bacteria in particular drive nitrogen fixation, most famously through the Rhizobia species that trade fixed nitrogen for sugar inside legume root nodules, and they compete aggressively with pathogens for the same space and food. Fungi split into two working groups: mycorrhizal fungi, which form direct symbiotic partnerships with roots and extend a plant's effective reach for water and phosphorus far beyond what the root itself could access, and saprophytic fungi, which decompose dead organic matter and physically bind soil particles together with their mycelium. Above them, protists graze on bacteria and release the nitrogen they contain as plant-available ammonium, while nematodes feed on bacteria, fungi, other nematodes, or roots depending on the species, and in doing so regulate the size of every population beneath them.

On paper, this reads like a food chain. In practice, it behaves more like an economy — thousands of overlapping transactions happening in the thin films of water around every soil particle, all of it ultimately funded by whatever the plant's roots are putting into the ground. And that's the part this week's study actually gets inside of.

The Study: What Happens When a Fungus Moves Into the Root Zone

Researchers R. N. Ames, C. P. P. Reid, and E. R. Ingham — yes, that Ingham, the same microbiologist whose work popularized the term "soil food web" in the first place — grew blue grama grass in sandy, nutrient-poor soil collected from a Colorado grassland. Half the plants were inoculated with Glomus mosseae, a vesicular-arbuscular mycorrhizal (VAM) fungus, at transplant. The other half were grown exactly the same way, without the fungus. Both groups had the same five species of naturally occurring rhizosphere bacteria inoculated into their soil from the start, so every plant began with an identical microbial starting lineup.

Sixty days later, the researchers harvested everything and counted. They measured bacterial populations in the soil that fell away from the roots easily — the "non-rhizosphere" soil — and separately in the soil that clung tightly to the root surface, the true rhizosphere zone. They also measured how much of each root system the mycorrhizal fungus had actually colonized, and cross-checked all of it against root length, root branching, and shoot growth.

Non-Rhizosphere Soil

Soil that fell away from the root easily during handling — the general soil body, still influenced by the plant but not in direct root contact.

Rhizosphere Soil

Soil still clinging to the root surface after gentle shaking — the immediate zone shaped directly by root exudates and root-surface chemistry.

The distinction matters more than it sounds like it should. The rhizosphere is a genuinely different biological neighborhood from the soil a few millimetres further out — a definite zone, as the researchers put it, existing as little as two to four millimetres from the root surface. If a mycorrhizal fungus changes anything about bacterial life, this is where you'd expect to see it first.

The Fungus Barely Colonized the Root — And Still Changed the Neighborhood

Here's the detail that should reframe how growers think about mycorrhizal inoculation: colonization of the root system by G. mosseae topped out at only 5.5% of the lateral root length measured. This wasn't a case of the fungus taking over the root system and obviously dominating its biology. It was a light, partial colonization — and it was still enough to produce measurable, statistically significant shifts in the surrounding bacterial community.

Not More Bacteria — Different Bacteria

The most common assumption about "living soil" is that more biological activity is uniformly better — more bacteria, more fungi, more of everything, all the time. This study complicates that picture in a useful way. Regardless of which measurement basis the researchers used, one bacterial species — a fluorescent, oxidase-positive Pseudomonas-type isolate labelled CB11 — increased significantly in the rhizosphere of mycorrhizal plants compared with non-mycorrhizal ones, in three of the five comparison methods tested. Its numbers correlated with how much of the root system was mycorrhizal, and separately with how many mycorrhizal lateral roots existed.

That last point is the one worth sitting with. It isn't just that individual bacterial populations moved up or down. The relationships between different bacteria changed depending on whether a mycorrhizal fungus was present at all. Two species that behaved independently of each other in ordinary soil started behaving as a pair once the fungus arrived. That's not a change in quantity. That's a change in the structure of the community itself — which is precisely the kind of thing the term "soil food web" is trying to describe, and precisely the kind of thing that's nearly impossible to see without an experiment built to isolate it.

"The mycorrhizal fungus didn't just add another organism to the soil. It rewired which bacteria were connected to which — the kind of shift you'd never catch by counting biomass alone."

Root Exudates: The Currency Nobody Sees

The researchers' own explanation for these shifts centers on root exudation — the sugars, amino acids, and other compounds a root leaks into the soil around it, which serve as the primary food source for much of the rhizosphere's bacterial life. The working theory is that mycorrhizal colonization changes what and how much a root exudes, which in turn changes which bacteria can thrive nearby. It's a plausible mechanism, and it lines up with earlier work cited in the paper showing reduced sugar and amino acid content in root exudates from mycorrhizal plants compared with non-mycorrhizal controls of a different species.

But the authors are honest that this raises as much as it resolves. If mycorrhiza formation generally reduces root exudation, why would specific exudate-dependent bacteria like CB11 increase rather than decrease around mycorrhizal roots? Their answer, and ours: the soil food web doesn't run on a single tap that turns uniformly up or down. It's plausible the fungus is changing the exudate mixture rather than simply throttling its volume — favouring compounds that specific bacteria prefer, while starving out others. Nobody has measured that directly yet. It's a genuinely open question, which is a more honest place to land than pretending the mechanism is settled.

Why This Should Matter for Cannabis Growers Specifically

Cannabis forms its own arbuscular mycorrhizal relationships, and living-soil cultivation leans on that fact constantly — mycorrhizal inoculants are a staple ingredient in most living soil mixes and no-till beds. What this study adds isn't a claim about cannabis directly; blue grama grass and sandy Colorado rangeland soil are a long way from a cannabis root ball in a fabric pot. What it adds is a concrete, measured example of the mechanism living soil growers are actually relying on when they inoculate with mycorrhizal fungi at all: the fungus isn't just a nutrient-delivery shortcut for the plant. It's an organism that reaches into the surrounding bacterial community and reorganizes it — promoting some populations, suppressing others, and creating new relationships between bacterial species that didn't exist before it arrived.

The Honest Limitations

This is a forty-year-old study on a wild grass species, grown in a greenhouse pot for sixty days, in sandy Colorado rangeland soil with very low native nutrient levels. None of that is cannabis, none of it is a living soil bed, and none of it is a full growing season. The correlations reported — including the r = 0.53 relationship between CB11 and mycorrhizal colonization — are correlations, not proof that the fungus directly caused the bacterial shift; the researchers themselves note that the mechanism connecting the two remains genuinely unclear. Counts of one inoculated bacterial species, an Azotobacter, couldn't be reliably measured at all and were dropped from the analysis. And critically, results changed depending on how the data were expressed — per gram of rhizosphere soil, per gram of whole root, per gram of lateral root, per centimetre of lateral root, or per number of root branches all told a slightly different statistical story, which the authors themselves flag as a problem still unresolved in this field: there's no agreed-upon standard for how to measure a rhizosphere population in the first place.

None of that erases the value of what was shown. This remains one of the few studies that isolated a single mycorrhizal fungus-bacteria interaction cleanly enough to put numbers on it, rather than just observing that "biology was different" between treatments. For a series that keeps circling back to the same idea — that soil is a web of relationships, not a stack of independent ingredients — this is what that idea looks like in raw data, decades before "living soil" was a marketing term.

Mycorrhizal fungus and rhizosphere bacteria interaction: Ames, R. N.; Reid, C. P. P.; Ingham, E. R. Rhizosphere Bacterial Population Responses to Root Colonization by a Vesicular-Arbuscular Mycorrhizal Fungus. New Phytologist 1984, 96, 555–563. Natural Resource Ecology Laboratory, Colorado State University, Fort Collins, Colorado.
Foundational soil food web framing: Concept popularised by Dr Elaine Ingham and drawn from Jeff Lowenfels' Teaming with Microbes, as introduced in our earlier post, "What is the Soil Food Web?"
Posted on

Underground Medicine: What the Root Was Doing the Whole Time

Discover how two new studies prove that cannabis roots carry powerful, non-psychoactive anti-inflammatory and pain-relieving chemistry.
Underground Medicine — What Two 2025 Studies Found Hiding in the Cannabis Root | The Certified
Root Chemistry · Pharmacology

We've spent this cultivation arc underground — cover crops, compost timing, manure ratios, and what all of it does to the rhizosphere. This week we go one step further and look at the root itself, not just what it pulls in from the soil. Two separate 2025 studies tested cannabis root extract directly, in living pain models and in human immune cells, and both came back with the same underlying message: the part almost everyone throws away or burns has its own medicine.

Root Chemistry · Endocannabinoid System · Biotechnology · Research

Underground Medicine — What the Root Was Doing the Whole Time

Growers have suspected it for centuries and mostly composted it anyway. Two new 2025 studies — one on field-grown root extract in rodent pain models, one on lab-cultured root extract in human immune cells — now give that old instinct a data trail. Here's what the science found, and what it should change about how you treat your root zone.

The Grower's Connect · · 15 min read
100% vs 0% two-week survival after acute pain induction — high-dose root extract vs untreated
On par with diclofenac root extract's anti-inflammatory effect in a standard paw-edema pain model
1 of 3 solvents extraction methods that didn't kill immune cells outright in lab testing
Root > Leaf lab-grown root extract outperformed leaf extract at suppressing inflammatory signalling
Listen to this article Underground Medicine
Audio coming soon — replace this div with your <audio> tag when ready

Every harvest ends the same way for most growers: the flower goes to the drying rack, the fan leaves go to the compost, the stalk gets chopped, and the root ball — the thing that spent the entire season doing the actual work of building the plant — gets pulled, shaken off, and either binned, burned, or tilled back under. Ask around and you'll find growers who half-suspect there's something in there worth keeping. Old-world hemp and cannabis traditions certainly thought so; root preparations for pain, fever, and joint complaints show up across centuries of folk medicine, long before anyone knew what a cannabinoid receptor was. But without trace THC or CBD to point to, the root has mostly stayed folklore — a thing growers feel is probably useful, without much reason to act on the feeling.

Two studies published in 2025 give that instinct a real foundation. Neither one is about the flower. Both are about the root — one grown conventionally in the field and extracted with ethyl acetate, tested directly in mice and rats dealing with real, induced pain and inflammation; the other grown as lab-cultured adventitious root tissue and extracted with methanol, tested against human dendritic cells and T cells, the immune system's own inflammatory machinery. Different labs, different countries, different extraction chemistry, different biological systems — and yet both landed on the same conclusion from two different directions: the root carries its own independent, non-psychoactive pharmacology, and it's strong enough to measure against real pharmaceutical comparators.

The Root That Kept Mice Alive

The first study, out of Dongguk University's College of Korean Medicine, took dried root from Korean-grown Cannabis sativa, extracted it in 70% ethanol, and fractionated it down to the ethyl acetate layer — the fraction their earlier work had already flagged as the most anti-inflammatory of the bunch. They called it CSREA, and they ran it through three classic pain-and-inflammation models: a formalin injection that produces a sharp early pain response followed by a slower inflammatory one, an acetic-acid "writhing" test used across decades of analgesic research, and a carrageenan-induced paw-swelling model in rats, the standard test for how well something controls acute inflammation.

Mice pre-treated with the higher dose of root extract showed a significantly smaller pain response than untreated mice in both the early, nerve-driven phase and the later, inflammation-driven phase of the formalin test — and in the later phase, it outperformed diclofenac, the pharmaceutical NSAID used as the study's positive control. In the paw-edema model, the root extract suppressed swelling and redness at a level the researchers described as dose-dependent and comparable to diclofenac. But the number that actually stops you mid-scroll is the survival data.

That's not a subtle trend line in a bar graph. That's every animal in the high-dose root-extract group making it through, in a model where every untreated animal did not, and where the standard pharmaceutical treatment saved fewer than half. The researchers were careful to frame this as one dataset from one lab, not a therapeutic claim for humans — and so are we — but it's precisely the kind of result that explains why "the root does something" survived as folk knowledge for this long.

How It Works: The Root Talks to Your Endocannabinoid System

Mechanism is where this gets genuinely interesting for anyone who's been following our endocannabinoid-system coverage. The Dongguk team ran parallel experiments in retinoic-acid-differentiated neuronal cells and found that the root extract was doing something specific: rebalancing the ratio between the two main cannabinoid receptors, CB1 and CB2, back toward a healthier baseline, while simultaneously down-regulating FAAH and MAGL — the two enzymes responsible for breaking down your body's own natural endocannabinoids.

"Less enzyme breaking the signal down means more of your own endocannabinoid tone left standing — the root doesn't add cannabinoids, it protects the ones your body already makes."

The same cells showed something else worth flagging for anyone thinking about neuropathic pain specifically: three genes tied directly to pain signalling — a sodium channel called Nav1.7, an acid-sensing channel called ASIC1A, and a substance-P receptor called TACR1 — were all elevated under the stressed cell state, and all significantly reduced by root extract treatment at the higher dose. This is a root with trace cannabinoid content acting on the exact molecular machinery that determines how much pain a nerve cell transmits in the first place.

The Second Study: Roots Grown in a Lab, Same Underlying Story

The second paper comes from Korea's Research Institute of Bioscience and Biotechnology and takes a completely different route to the root. Instead of digging up field-grown plants, the team induced adventitious roots — a lab-cultured root tissue grown from leaf cuttings under sterile, controlled conditions, a technique already used across the medicinal plant world to produce consistent, reproducible metabolite profiles without the variability of open-field growing. They extracted this lab-grown root tissue three ways — hexane, chloroform, and methanol — and tested each against bone-marrow-derived dendritic cells, the immune system's first responders, and against T cells, the cells dendritic cells activate downstream.

The first finding is one every extractor should sit with: solvent choice wasn't a minor detail, it was the difference between medicine and toxin.

Hexane & Chloroform Extracts

Both induced measurable necrotic and apoptotic cell death in immune cells at concentrations as low as 10 micrograms per millilitre, worsening sharply at higher doses. Where they did suppress inflammatory cytokines, they simultaneously increased IL-1β — the opposite of what you want from an anti-inflammatory.

Methanol Extract

Showed no cytotoxicity at any tested concentration, and delivered broad-spectrum suppression of every inflammatory cytokine measured — including IL-1β, the one the other two solvents couldn't touch — with the effect strengthening as the dose increased.

From there, the methanol root extract kept delivering. Under immune-triggering conditions, it held dendritic cells in an immature, non-inflammatory state — suppressing the surface markers that signal "fully activated," restoring the antigen-uptake ability that normally shuts off once a dendritic cell matures, and reducing the cell's ability to actually present antigens to T cells in the first place.

Root Beat Leaf — In Its Own Study

Why Your Root Zone Now Carries More Weight

This is where the two root studies connect directly back to what we covered a few weeks ago on manure sourcing and heavy metal mobility. Neither of these papers tested how soil practices change root phytochemistry — that link hasn't been measured yet, and we're not going to pretend it has. But the underlying biology makes the connection hard to ignore.

In other words: the soil stewardship this series has been building toward — knowing your manure source, testing compost maturity instead of guessing, favouring cover cropping over aggressive tillage — was always going to matter for flower quality. Now it matters for a second harvestable tissue too, and that tissue is the one organ built specifically to absorb whatever is in the ground beneath it.

What This Means for Your Next Harvest

The Honest Limitations

Both studies were preventative rather than therapeutic in design — the root extract went in before the pain or inflammation was induced, which is standard for early-stage screening but doesn't map directly onto treating pain that's already established. Dosing in the pain study wasn't matched to diclofenac on an equipotent basis, so "on par with" and "outperformed" describe the doses actually tested, not a settled comparison of maximum effectiveness. The mechanism work used a differentiated neuroblastoma cell line, not primary neurons, over a six-hour treatment window. And the adventitious root system in the second study is lab-cultured from leaf tissue under sterile conditions — genetically and metabolically stable by design, but not the same thing as a root pulled from a field-grown plant, so its chemistry may not map one-to-one onto what you'd actually harvest from your own root zone. Group sizes were modest, and researchers in both studies knew which animals or cells received which treatment throughout, so blinding wasn't part of either design.

None of that erases the core finding. Two independent teams, working with different extraction chemistry in different biological systems, both found real, measurable, mechanistically explainable activity in a plant organ most growers have never thought to test. That's not proof the root belongs in your medicine cabinet tomorrow — but it's more than enough reason to stop treating it as waste.

Field-grown root extract, pain and inflammation: Jang, S.-Y.; Jin, H.-L.; Yu, G.-R.; Lim, D.-W.; Park, W.-H. Cannabis sativa Root Extract Exerts Anti-Nociceptive and Anti-Inflammatory Effects via Endocannabinoid Pathway Modulation In Vivo and In Vitro. Int. J. Mol. Sci. 2025, 26, 8863. doi:10.3390/ijms26188863 — College of Korean Medicine, Dongguk University, Republic of Korea.
Lab-cultured adventitious root extract, immune cells: Park, S.H.; Han, J.M.; Kim, Y.H.; Lee, H.J.; Ryu, Y.B.; Ryu, H.W.; Jeong, J.C.; Oh, S.M.; Kim, W.S. Biotechnological Potential of Cannabis sativa Adventitious Roots for Producing Immunomodulatory and Anti-Inflammatory Bioactive Compounds. Scientific Reports 2025, 15, 30904. doi:10.1038/s41598-025-16130-1 — Korea Research Institute of Bioscience and Biotechnology, Republic of Korea.
Posted on

The Compost Clock

The Compost Clock
The Compost Clock — Manure Timing & Blends for Cannabis | The Certified
Cultivation Science · Composting

Continuing our cultivation science arc — last week we looked at how cover cropping versus tillage reshapes cannabinoid and terpene profiles. This week we go one layer deeper: what's actually going into that soil, and how long it needs before it's ready. We're bringing together three separate studies — on compost maturation timing, combined organic-and-inorganic fertilization in hemp, and manure's effect on heavy metal mobility — and reporting back where they agree.

Cultivation Science · Soil Health · Composting · Research

The Compost Clock — What the Data Actually Says

Growers love mixing raw manures and stretching synthetic fertiliser with organic inputs. Three studies — on compost timing, combined organic-inorganic feeding, and manure-driven heavy metal mobility — show it can genuinely work. But maturity isn't optional, ratio isn't cosmetic, and manure source carries real consequences.

The Grower's Connect · · 14 min read
30 days to full compost maturity under the best-performing manure ratio
101% vs 61% germination index at day 30 — best manure ratio vs the one that failed to mature
≈0% growth gain from raw, uncomposted digestate vs a properly composted blend
+170% cannabinoid yield from the best organic-plus-reduced-mineral blends
Listen to this article The Compost Clock
Audio coming soon

Ask ten growers what "the compost is ready" means and you'll get ten different answers. Some go by smell. Some go by colour. Some go by a date circled on a calendar three or four weeks after the pile went down. Almost none of them are testing for it directly, and almost none of them are thinking carefully about what manure they used to build the pile in the first place.

That gap — between compost-by-feel and compost-by-data — is where this week's reading sits. We pulled together three studies that, between them, cover the whole chain a grower actually cares about: how long composted manure takes to stop being immature and start being safe, what happens to plant growth and cannabinoid chemistry when you combine organic inputs with a reduced rate of synthetic fertiliser, and — the part almost nobody talks about — what manure application does to heavy metal mobility in soil, given that cannabis itself is an unusually efficient metal accumulator. None of the three studies used identical crops or conditions, so we're not stitching them into one seamless story. But where they line up, the agreement is worth taking seriously, and where they diverge, that's useful information too.

How Long Does Compost Actually Take?

A 2023 study out of Anhui University of Science and Technology in China set out to answer this with real numbers. Researchers composted wheat straw with pig manure or cow manure at 20%, 30%, and 40% ratios, plus a microbial inoculant, and tracked the pile daily for thirty days — temperature, pH, electrical conductivity, nitrogen forms, and a seed germination index, the standard lab proxy for whether a compost is mature enough to stop harming plants.

Under the best-performing ratio in this study — 40% cow manure to 60% wheat straw — the germination index reached 101% by day thirty, comfortably past the "fully mature" threshold. That treatment also showed the fastest organic matter breakdown and the best nitrogen and phosphorus retention of any group tested. Thirty days, with turning every two to three days, was enough to get there.

"The calendar date isn't the test. The germination index is the test — and one manure ratio in this study never crossed the finish line by day thirty."

Manure Ratio Matters More Than Manure Amount

Here's the part growers mixing raw manures need to sit with: not all manure-to-straw ratios matured at the same rate, and more manure was not automatically better. The treatment using 40% pig manure was the standout underperformer across the board.

Cow Manure — Scales Well

Organic matter degradation rate and nitrogen/phosphorus retention both improved as the cow manure ratio increased, peaking at 40%. The 30% and 40% cow manure treatments were the two best performers overall on the study's combined maturity score.

Pig Manure — Doesn't

At 40% pig manure, the pile's germination index actually fell below its pre-composting starting point, ending at 61% by day thirty — the only treatment that failed to reach full maturity. The researchers concluded excess pig manure actively inhibited pile decomposition rather than accelerating it.

The overall ranking, using the study's combined "how decomposed is this pile" score across nine indicators: 40% cow manure came out on top, followed by 30% cow manure, then the unamended straw-only control, then the lower pig manure ratios, with 40% pig manure dead last — worse than doing nothing at all. If you're building your own manure blend this spring, that's a concrete, tested reason to lean toward cow manure over pig manure when pushing ratios higher, and to be cautious about assuming "more manure, more nutrients, better compost" holds in a straight line.

What Happens When You Skip the Cure

The composting study above is about wheat straw, not cannabis directly. But a separate 2025 field trial on industrial hemp, run by Italy's Council for Agricultural Research and Economics, gives a striking real-world echo of the same lesson — using an actual hemp crop.

Researchers tested nine fertility treatments on field-grown hemp: no fertiliser, full synthetic NPK, six different composted blends of solid digestate with cardoon waste or spent mushroom substrate, and — critically — the same solid digestate used raw, uncomposted, all paired with half the normal synthetic nitrogen rate. Every composted blend except one modest underperformer produced meaningfully more plant growth and phytochemical accumulation than the unfertilised control. The raw digestate did not.

Put plainly: two organic inputs went into the same field at the same nutrient rate, and only one of them had been given time to mature. The one that hadn't performed almost identically to no fertiliser at all. That's the composting study's warning, showing up independently in an entirely different crop, on an entirely different continent.

The Organic-Plus-Reduced-Synthetic Combo That Actually Worked

The hemp trial's more encouraging finding is the one growers asking about cost-effectiveness will want: replacing half the synthetic nitrogen rate with a well-matured compost did not come at the expense of growth or chemistry — for the right blends, it matched or beat full-rate synthetic fertiliser.

The Heavy Metal Caveat Almost Nobody Talks About

Here's the piece that tends to get skipped when growers discuss manure blends purely in terms of nitrogen, phosphorus, and potassium: manure doesn't only deliver nutrients. If the manure — or the soil it's going into — carries any heavy metal load, cannabis is unusually good at pulling it into a more available, more uptake-ready form.

A 2012 Iranian study tested this directly on a lead- and cadmium-contaminated soil, treating it with cow manure, poultry manure, and their water extracts, then growing cannabis in it for eight weeks. This is a more extreme scenario than most growers will face — the soil was deliberately built from mine-contaminated material — but the directional findings are worth knowing.

What This Means for Your Next Compost Pile

The Honest Limitations

These three studies weren't designed to be read together, so some caution is warranted in how far we stretch the connections. The composting study used wheat straw and never tested cannabis directly — its germination index readings came from cucumber seeds, a standard proxy, not from cannabis itself. The hemp fertilisation trial used composted digestate and cardoon waste, not the manure-and-straw blends from the composting study, so the specific ratios don't transfer directly. And the heavy metal study used a soil deliberately built to be heavily contaminated, cultivated for only eight weeks, in a single Iranian cannabis cultivar under greenhouse conditions — a long way from a typical outdoor grow. What connects them is the underlying pattern, not a single unified dataset: maturity and manure source are not incidental details, they are variables that measurably change what you harvest.

Taken together, these findings support what many growers already suspect from experience — combining organic and reduced-rate synthetic fertilisation is a genuinely viable, evidence-backed approach, not just a workaround. But the studies are equally clear that the benefit depends entirely on getting the input right before it goes in the ground: mature, well-ratioed, and sourced from land you actually trust.

Composting timeline: Fan T, Zhang X, Wan Y, Deng R, Zhu H, Wang X, Wang S, Wang X. Effect of Different Livestock Manure Ratios on the Decomposition Process of Aerobic Composting of Wheat Straw. Agronomy 2023, 13, 2916. doi:10.3390/agronomy13122916 — School of Earth and Environment, Anhui University of Science and Technology, China.
Organic-plus-inorganic hemp fertilisation: Sicignano M, Beleggia R, del Piano L, Enotrio T, Suriano S, Raimo F, Trono D. Effect of Combining Organic and Inorganic Fertilizers on the Growth of Hemp (Cannabis sativa L.) Plants and the Accumulation of Phytochemicals in Their Inflorescence. Plants 2025, 14, 1519. doi:10.3390/plants14101519 — Council for Agricultural Research and Economics (CREA), Italy.
Manure and heavy metal mobility: Safari Singani AA, Ahmadi P. Manure Application and Cannabis Cultivation Influence on Speciation of Lead and Cadmium by Selective Sequential Extraction. Soil and Sediment Contamination: An International Journal 2012, 21(3), 305–321. doi:10.1080/15320383.2012.664186 — Bu-Ali Sina University, Hamedan, Iran.
Posted on

What New Research Reveals About Cannabis and Alzheimer’s Disease

2025 review of 45 studies shows how CBD acts on amyloid and inflammation in Alzheimer's. A 2026 clinical trial shows a THC/CBD combination easing dementia agitation.
Grace at the End — What New Research Reveals About Cannabis and Alzheimer's Disease | The Certified
Research Deep Dive · Neurodegeneration

Stepping out of the growroom and into the clinic this week. We're pairing a 2025 review that maps everything the lab literature says CBD does inside an Alzheimer's brain, with a landmark clinical trial result reported at a major dementia research conference — literally yesterday — showing what a THC/CBD combination does for real patients at the end of life.

Neuroscience · Alzheimer's Disease · Clinical Trial News · 2025–2026

Grace at the End — What New Research Reveals About Cannabis and Alzheimer's Disease

A comprehensive 2025 review mapped 45 studies and 64 genes to show how CBD acts on the molecular hallmarks of Alzheimer's disease. A year later, the first randomized controlled trial of a THC/CBD combination in hospice-eligible dementia patients reported results — and they were significant, fast, and sustained.

The Grower's Connect  ·   ·  13 min read
45 studies reviewed, spanning nine biological pathways CBD affects in Alzheimer's models
64 genes CBD modulates, mapped onto five enriched biological pathways
120 hospice-eligible dementia patients in the first controlled trial of its kind
87.2% of treated patients improved by week 12, versus 23.6% on placebo
Listen to this article Grace at the End — What New Research Reveals About Cannabis and Alzheimer's Disease
Audio coming soon — replace this div with your <audio> tag when ready
Quick Answers & Key Takeaways
  • CBD's Action on Alzheimer's Biology: A 2025 review of 45 studies shows CBD influences amyloid-beta, neuroinflammation, and oxidative stress pathways.
  • The 2026 LiBBY Clinical Trial: The first Phase 2 randomized trial showed a THC/CBD combination significantly reduced agitation in hospice-eligible dementia patients within just 2 weeks.
  • Sustained Relief: By week 12, 87.2% of patients receiving THC/CBD showed clinical improvement in agitation compared to just 23.6% on the placebo.

Roughly half of people with dementia experience agitation in the final stage of the disease, when they become eligible for hospice care. Pacing. Calling out. Hitting, kicking or resisting care. Distress that a person nearing the end of their life often cannot put into words. For decades, clinicians treating this have had almost nothing built for the job — off-label antipsychotics, benzodiazepines and opioids, borrowed from other conditions, carrying real risks in a population that is already frail. There has never been a proper controlled trial testing an alternative in this specific group. Until this week.

On 14 July 2026, at the Alzheimer's Association International Conference in London, researchers presented topline results from the LiBBY trial — the first randomized, double-blind, placebo-controlled study of a THC/CBD combination in hospice-eligible dementia patients. The results were, in the words of lead investigator Jacobo Mintzer, a "robustly positive" step forward for a population that clinical research has largely overlooked. It lands almost exactly one year after a separate team in Brazil published the most complete map yet of what cannabidiol actually does, at a molecular level, inside an Alzheimer's-affected brain. Read together, the two papers tell a rare kind of story in medicine: the mechanism, and then the proof.

Why Alzheimer's Needs New Treatment Options

Alzheimer's disease is not one problem but several happening at once — amyloid-beta protein clumping between neurons, tau protein tangling inside them, chronic neuroinflammation, oxidative stress, and a slow collapse of the cholinergic signalling system the brain relies on for memory. The only widely used treatments, cholinesterase inhibitors, target just one piece of that puzzle, and their benefit is modest while their side effects — nausea, dizziness, cardiovascular complications — are not trivial, especially in older, frailer patients. A team at the Federal University of Paraná, Brazil, set out to systematically compile what the scientific literature actually says about cannabidiol as a candidate for filling that gap.

About the 2025 Review

The researchers searched PubMed and Web of Science for every paper matching "cannabidiol" and "Alzheimer's," with no date or study-type filter. Of 144 results, 45 original research articles survived screening to exclude reviews and papers that only mentioned the terms in passing. These 45 studies span in vivo, in vitro and in silico (computational) models, and together describe 61 distinct experimental outcomes across nine categories of Alzheimer's biology.

What 45 Studies Say CBD Does to an Alzheimer's Brain

Sorted by how much research attention each has received, five categories dominate the literature: amyloid-beta biology, behavioural changes, neuroinflammation, oxidative stress, and the cholinergic pathway.

Amyloid-β · 26.2% of Outcomes

CBD is linked to lower expression of the secretase enzymes that cleave amyloid precursor protein into Aβ fragments, and is described as a potential inhibitor of beta-secretase activity. In vivo models show reduced Aβ accumulation in the hippocampus and cortex, with CBD's ROS-scavenging ability proposed as one driver — less oxidative stress, less signal for Aβ production in the first place.

Neuroinflammation · 18% of Outcomes

Microglia, the brain's resident immune cells, switch between a resting state and an inflammatory one in response to Aβ. Studies show CBD blocking that transition, reducing pro-inflammatory cytokines and inducible nitric oxide synthase, and acting as an agonist at the PPAR-γ receptor to reduce inflammatory damage and promote new neuron growth in the hippocampus.

Oxidative Stress · 14.8% of Outcomes

Multiple cell and animal models show CBD reducing reactive oxygen species without triggering compensatory overexpression of oxidative-stress genes — protecting cells from oxidising agents and from methylglyoxal damage, and modulating mitochondrial dynamics genes disrupted by iron overload in neurodegeneration models.

Behaviour & Cholinergic Pathway · 18% + 8.2%

Across rodent AD models, CBD-treated animals consistently show better memory processing and exploratory behaviour than untreated controls. Separately, CBD reduces the activity of both acetylcholinesterase and butyrylcholinesterase — the same enzyme class current AD drugs target, but without their drug class's typical side-effect profile.

One human trial found that a daily three percent CBD regimen produced a significant improvement in behavioural and physiological symptoms of dementia, compared with conventional treatment — a rare piece of clinical, rather than preclinical, evidence in the whole dataset.

The Genetic Fingerprint of CBD

Beyond the narrative review, the team ran a computational analysis to see which specific genes CBD touches, and which biological pathways those genes belong to. Pulling from two studies that had measured gene expression changes after CBD treatment, they assembled a set of 64 CBD-modulated genes and tested it for pathway enrichment against the KEGG database — a standard bioinformatics technique for spotting whether a gene list clusters meaningfully around known disease pathways, rather than scattering randomly.

Five Pathways, One Signal

  • Alzheimer's disease pathway itself: genes tied to amyloid formation (PSEN1, PSEN2, BACE1, NCSTN) and neurodegeneration mechanisms clustered here, the strongest and most expected result.
  • Neurotrophin signalling: genes supporting neuron differentiation and maintenance, including kinase-signalling genes like AKT1 and the PIK3 family, which regulate cell survival and neurite growth.
  • Pathways of neurodegeneration — multiple diseases: a broader KEGG category capturing shared mechanisms — proteasome dysfunction, mitochondrial abnormalities — across several neurodegenerative conditions, not just Alzheimer's.
  • Lipid and atherosclerosis pathway: genes from the CAMK2 and heat-shock protein families, connecting CBD's action to lipid metabolism and to chaperone proteins that help prevent Aβ and tau aggregation.
  • Shigellosis — an unexpected fifth pathway: not an infection finding. This bacterial-infection pathway shares ubiquitination machinery with Alzheimer's protein-clearance mechanisms, and its appearance here reflects CBD's effect on ubiquitin-related genes rather than anything to do with dysentery.

Then the Real News — The LiBBY Trial

Everything above is preclinical or mechanistic — mice, worms, cell lines, gene lists. It is exactly the kind of evidence a 2025 review would flag as promising but incomplete, and the Brazilian team said so directly: current clinical evidence for CBD in Alzheimer's disease remains limited, most human studies combine CBD with other cannabinoids in ways that muddy interpretation, and there had been no randomized Phase III trial focused specifically on AD. That is the gap the LiBBY trial — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol — was built to address, in the single symptom that causes the most suffering at the very end of the disease: agitation.

About the Trial

LiBBY was a multicenter, randomized, double-blind, placebo-controlled Phase 2 study run by the NIA-funded Alzheimer's Clinical Trial Consortium across multiple U.S. sites. It enrolled 120 hospice-eligible participants with Alzheimer's or another dementia and clinically significant agitation — mean age 80.5, 55% female, 58% from underrepresented ethnoracial groups. Participants received an oral THC/CBD formulation dissolved in digestible oil (a half dose of 2mg THC/100mg CBD twice daily for the first week, stepping up to a full dose of 4mg THC/200mg CBD twice daily for weeks two through twelve) or a matched placebo. Agitation was measured using the Cohen-Mansfield Agitation Inventory, a standard clinical scale.

The trial hit both its primary and key secondary endpoints, and the effect size was large by clinical-trial standards. At two weeks, the treatment group showed a 6.27-point greater reduction in agitation scores than placebo — a statistically significant, rapid effect. By twelve weeks, that gap had widened to an 8.23-point greater reduction, meaning the benefit wasn't just fast, it held. Clinician-rated global improvement told the same story from a different angle.

LiBBY — The Headline Numbers

  • Week 2 agitation reduction: 6.27 points greater in the THC/CBD group than placebo (p=0.0004).
  • Week 12 agitation reduction: 8.23 points greater in the THC/CBD group than placebo (p<0.0001), showing the effect was sustained, not fading.
  • Clinician-rated improvement, week 2: 83.9% of treated participants improved, versus 30.5% on placebo.
  • Clinician-rated improvement, week 12: 87.2% of treated participants improved, versus 23.6% on placebo.
  • Adverse events: similar overall rates between groups (46.7% treatment vs 42.4% placebo). Serious adverse events were more frequent in the treatment arm (23.3% vs 11.9%), though investigators determined none were related to the study medication.

Beyond the numbers, the investigators highlighted something just as important as the result itself: this population — hospice-eligible dementia patients, disproportionately excluded from clinical trials — could be recruited, enrolled and retained, including participants from historically underrepresented communities. Three-quarters of participants lived in community settings rather than institutions. Paul Aisen, one of the trial's principal investigators, called it proof that "high-quality clinical research can and should be conducted in people with advanced dementia," a population most drug development has simply passed over.

Reading These Two Papers Together

It's worth being precise about what connects these studies and what doesn't. The Brazilian review's molecular evidence is built almost entirely on isolated CBD — in mice, worms and cell lines, targeting amyloid, tau, inflammation and oxidative stress broadly across the disease course. LiBBY tested a THC/CBD combination, not CBD alone, in a single late-stage population, for a single symptom: agitation, not cognitive decline or amyloid burden. LiBBY doesn't confirm the amyloid or tau mechanisms the review describes, and the review's molecular story doesn't explain why adding THC specifically helped with agitation. What the two papers do together is bracket the picture — one showing plausible biology across the whole disease, the other showing a real clinical effect at one specific, brutal moment near its end.

What Neither Study Fully Answers

Both papers are honest about their own limits, and it's worth sitting with them rather than skipping past. The review's authors note that their gene-expression analysis rests on just two source studies and 64 genes — a starting map, not a finished one — and that their literature search, by design, excluded studies that examined CBD's mechanisms without explicitly tying them to Alzheimer's disease, which may have left relevant evidence out. More strikingly, they found no studies in their search that directly examined CBD's potential adverse effects or toxicity in the Alzheimer's context specifically — a genuine blind spot, given that CBD is known elsewhere in the literature to carry a dose-dependent risk of liver enzyme elevation and to inhibit several cytochrome P450 enzymes, raising real drug-interaction concerns in older patients typically on multiple medications.

LiBBY, for its part, is a Phase 2 trial, not the Phase 3 evidence typically required before a treatment becomes standard practice. It tested one specific dose, one specific population, and one specific symptom over twelve weeks — it says nothing about whether THC/CBD affects the underlying disease process, and the higher rate of serious adverse events in the treatment arm, even though unattributed to the drug, is a detail worth tracking rather than glossing over as the open-label extension phase reports its own results. Real answers about long-term safety, optimal dosing and disease-modifying potential are still ahead, not behind.

What This Actually Means Right Now

  • Not a Cure Neither paper claims CBD or THC/CBD reverses or halts Alzheimer's disease. The review documents plausible protective mechanisms; LiBBY documents symptom relief for agitation specifically, in the disease's final stage.
  • Complementary, Not Replacement The review's own authors position CBD as a possible complement to existing cholinesterase inhibitors, particularly for patients who tolerate current drugs poorly — not a substitute for them.
  • Different Products, Different Claims Most of the molecular evidence concerns isolated CBD. LiBBY's benefit is specifically for a defined THC/CBD combination at defined doses — the two are not interchangeable, and neither generalises automatically to over-the-counter CBD products of unknown composition.
  • A Population Finally Included Perhaps the most significant outcome of LiBBY, independent of the drug itself, is proof that hospice-eligible dementia patients can be safely and ethically enrolled in rigorous clinical trials — opening the door to more research in a group medicine has largely left behind.
  • Shared Decision-Making Still Applies The Alzheimer's Association's own response to these findings recommends non-pharmacological strategies as a first-line approach to agitation, with careful, individualised review of any pharmacological option alongside patients, families and clinicians.

What makes this pairing worth sitting with is the shape of the story, not just the numbers. A year ago, the honest scientific answer to "does CBD help with Alzheimer's" was: plausibly, mechanistically, in a lot of different ways, but nobody has properly tested it where it matters most. This week, for one of the disease's most distressing symptoms, in one of the populations medicine has most often excluded, somebody finally did.



Source Study 1: Mello-Hortega JV, de Oliveira CS, de Araujo VS, Furtado-Alle L, Tureck LV, Souza RLR. Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions. European Journal of Neuroscience 2025, 62:e70229. doi:10.1111/ejn.70229 — Polymorphisms and Linkage Laboratory, Department of Genetics, Federal University of Paraná, Curitiba, Brazil. Received 9 May 2025; Accepted 2 August 2025.
Source Study 2: Mintzer J, et al. Topline Results From ,LiBBY Trial Show THC/CBD Combination Significantly Reduces Agitation for People With Dementia at End of Life. Presented at the Alzheimer's Association International Conference (AAIC) 2026, London, 14 July 2026. The Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (LiBBY) study — Alzheimer's Clinical Trial Consortium, funded by the National Institute on Aging (R01AG068324-01) and the Alzheimer's Association. Presenting author: Jacobo Mintzer, M.D., Medical University of South Carolina / Ralph H. Johnson VA Healthcare System.
Posted on

THE GHOST IN THE BOTTLE: HOW CBD TURNS ITSELF INTO THC, HHC AND CBN

cbd turns intself into thc
The Ghost in the Bottle — How CBD Turns Itself Into THC, HHC and CBN | The Certified
Cultivation Science · Processing & Storage

Continuing the cultivation science arc. We have covered harvest timing, AI readiness tools, bud rot, and eight years of curing data. This week we look at something growers and processors rarely think about: what acid does to CBD, and why the same chemistry behind the "legal HHC" market can switch on by accident, in a bottle, with no lab involved.

Cultivation Science · Processing Chemistry · Cannabinoid Safety · Research 2023

The Ghost in the Bottle — How CBD Turns Itself Into THC, HHC and CBN

A 2023 study out of Kyung Hee University put isolated CBD into mildly acidic ethanol and simply waited. No catalyst, no pressure chamber, no intent to synthesise anything. Within hours, the CBD was gone — and eight new compounds had taken its place, several of them psychoactive.

The Grower's Connect  ·   ·  11 min read
8 new compounds detected from one sample of acid-treated CBD
95% of CBD degraded within 5 hours at pH 2.0 and 70°C
pH 5.0 the threshold below which degradation barely happens at all
16 cannabinoids identified across every condition tested in this study
Listen to this article The Ghost in the Bottle — How CBD Turns Itself Into THC, HHC and CBN
Audio coming soon — replace this div with your <audio> tag when ready

Quick Answer: Can CBD Convert to THC or HHC?

  • Yes, CBD can convert to THC: Research confirms that exposing CBD to mildly acidic conditions (pH 2.0 to 3.5) causes it to naturally degrade into Delta-9 and Delta-8 THC.
  • HHC Formation: Without an industrial lab, acid-treated CBD dissolved in ethanol can undergo solvent addition to form ethoxy-HHC or methoxy-HHC analogs.
  • Storage Matters: Products formulated with citric acid (like gummies) or stored in warm environments accelerate this CBD degradation process.

Human stomach acid sits somewhere between pH 1.5 and pH 3.5. That is not a coincidence for this article — it is close to the exact range a team of South Korean researchers chose when they set out to answer a question the CBD industry has mostly avoided asking directly: what actually happens to cannabidiol when it sits in an acidic environment for a while? Not in a clandestine lab with a hydrogen tank and a palladium catalyst, but in the ordinary acidic conditions a CBD product might encounter — a citrus-flavoured gummy, a vinegar-preserved tincture, a bottle that got warm in transit, or simply a stomach after being swallowed.

The answer, published in the Journal of Food and Drug Analysis in 2023 by a team from Kyung Hee University, Kookmin University and Woosuk University, is not reassuring. Isolated CBD dissolved in ethanol and mildly acidified with hydrochloric acid began converting — on its own, at temperatures as low as 30°C — into a small chemistry set of psychoactive compounds. Delta-9 THC. Delta-8 and delta-10 THC. Cannabinol. Cannabichromene. And a family of alkoxy-substituted compounds the researchers themselves describe as HHC analogs.

Why CBD to HHC Conversion Matters for Cannabis Processors

We have written before about hexahydrocannabinol and the vape-shop version of the "legal high" argument — a semi-synthetic cannabinoid made by hydrogenating CBD under a metal catalyst and high pressure, deliberately, in an industrial setting. This study asks a different and in some ways more unsettling question: does CBD need a lab to start moving in that direction at all? The double bond that commercial HHC producers saturate with hydrogen gas turns out to be reactive enough that it will also react with whatever solvent it happens to be sitting in, given nothing more than acid and time. No catalyst required. No intent required.

About the Method

The researchers isolated 85 milligrams of pure CBD from cannabis inflorescence, dissolved it in ethanol, and adjusted the solution to pH 2.0, 3.5 or 5.0 using dilute hydrochloric acid. Samples were incubated at 30°C, 50°C or 70°C for periods ranging from one hour to twenty-four hours, then chemically tagged (a process called trimethylsilyl derivatisation) and run through gas chromatography–mass spectrometry, an analytical technique that separates and identifies individual compounds in a mixture by their mass fragments. This let the team track exactly how much CBD remained and exactly what it had turned into, at every combination of acidity, heat and time.

The Acid Degradation Pathway: How CBD Converts to THC and HHC

The transformation is not random. It follows a small number of well-defined chemical pathways, all starting from the same first step: acid activates the double bond in CBD's side chain, forming a positively charged carbon centre that is desperate to react with something.

Ring Closure → Delta-9 THC

The charged carbon reacts with CBD's own phenol group, folding the molecule closed into a new ring. This is the classic pathway to delta-9 THC, and it was the dominant early product in this study's ethanol solutions — the same reaction proposed to explain why CBD can convert to THC in simulated gastric juice.

Isomerisation → Delta-8 / Delta-10 THC

Once formed, delta-9 THC is not the end of the story. Continued acid exposure shifts the position of its double bond, producing delta-8 THC and delta-10 THC as minor but persistent by-products that kept accumulating for the full twenty-four hours tested.

Solvent Addition → Ethoxy/Methoxy-HHC

Instead of closing back into the ring, the charged carbon can instead grab a piece of the solvent itself — ethanol or methanol. The result is a hexahydrocannabinol-analog structure: the same skeleton commercial HHC is built on, but with an ethoxy or methoxy group sitting where a second hydrogen atom would normally go.

Oxidation & Ring Rearrangement → CBN and CBC

Separately, delta-8 THC can lose two hydrogen molecules to aromatise into cannabinol, while a distinct ring-opening and re-closing sequence produces cannabichromene. CBC's formation from acid-treated CBD had not been reported before this study.

Below pH 5.0, cannabidiol barely moves — even after twenty-four hours at seventy degrees Celsius. Push the same solution to pH 2.0, and it is largely gone within five hours.

The pH Threshold: At What Acidity Does CBD Degrade?

Of everything the study measured, acidity turned out to matter more than heat or time. At pH 5.0, essentially no degradation occurred, regardless of how hot or how long the reaction ran. At pH 3.5, degradation became measurable within five to ten hours. At pH 2.0, it was fast: roughly ninety-five percent of the CBD was gone within five hours at 70°C, and none remained detectable by the ten-hour mark. Delta-9 THC itself followed the same arc — it rose quickly, peaked around the five-hour point, and then began falling as it was further converted into ethoxy-HHCs, isomerised THCs and other products. A product tested once, early, would show clean CBD. Tested again later in its shelf life, it might not.

What The Numbers Actually Showed

  • pH 5.0, any temperature, 24 hours: no meaningful CBD degradation observed. This was the clearest safety margin in the entire dataset.
  • pH 3.5, 70°C: degradation and THC formation both increased steadily over the first ten hours.
  • pH 2.0, 30°C: degradation still occurred, just slower — acid alone, without much heat, was enough to start the reaction.
  • pH 2.0, 70°C: the fastest condition tested. CBD fell first-order over the first five hours; by ten hours it had disappeared from the chromatogram entirely.
  • Reaction solvent matters: in methanol instead of ethanol, the same pathway produced methoxy-HHC analogs instead of ethoxy ones — direct evidence that the solvent itself becomes part of the final molecule.

8 Psychoactive By-Products Formed from CBD Acid Degradation

At the most acidic, hottest, longest condition tested — pH 2.0, 70°C, twenty-four hours — the researchers identified eight distinct transformed products in a single reaction. Cannabichromene, delta-9 THC, and two ethoxy-HHC isomers were the major components. Delta-8 THC, delta-10 THC, cannabinol and a hydroxy-HHC derivative showed up as minor components. Across the full study, including parallel experiments on whole cannabis extract, the team catalogued sixteen cannabinoids in total — among them eight compounds structurally classed as THC isomers, all considered potentially psychoactive, alongside CBN and the methoxy- and ethoxy-HHC analogs.

Some of these were confirmed against authentic reference standards — THC isomers, CBC and CBN all matched known compounds exactly on retention time and mass spectrum. The HHC analogs and the hydroxy-HHC derivative were identified more tentatively, by matching chromatographic behaviour and interpreting their fragmentation patterns, because no commercial reference standards exist for them yet. That is itself a telling detail: these are compounds well-resourced analytical labs cannot buy a certified standard for, let alone the average processor trying to test a finished product.

The Ghost Doesn't Need A Lab

Commercial HHC is made deliberately — CBD is bombarded with hydrogen gas under a metal catalyst and pressure, in a controlled industrial process. This study shows a much lower bar gets you partway to the same neighbourhood of chemistry. Ordinary acid, ordinary ethanol, and time are enough to start converting that same reactive double bond — not into hydrogenated HHC itself, but into closely related alkoxy- and hydroxy-substituted cousins, plus a full slate of THC isomers and CBN. The synthetic ghost from the vape shop can, under the wrong storage conditions, start forming quietly in a bottle nobody meant to synthesise anything in.

Best Practices for CBD Processing and Storage to Prevent Degradation

None of this is abstract chemistry for growers who stop at flower. But for anyone extracting, formulating, bottling or storing CBD products — which is an increasing share of the South African cannabis economy — this study has direct, practical teeth.

Applied Implications for Manufacturers

  • Acidic Formulations CBD gummies and beverages acidified with citric or malic acid, or tinctures preserved with vinegar or low-pH alcohol, sit within the reactive window this study demonstrates. Checking and logging the actual pH of a finished formulation — not just the raw extract — is worth doing, especially for products with a long intended shelf life.
  • Heat in Transit The study shows degradation still proceeds, just more slowly, at 30°C — an ordinary hot day in a delivery vehicle or a warehouse without climate control. Time and mild heat compound the effect of any residual acidity in a product.
  • Residual Extraction Acids Processes that use acid catalysts or acidic wash steps during extraction or winterisation need thorough neutralisation. Incompletely neutralised residues left in a finished oil are a slow-motion version of exactly the reaction this study ran deliberately.
  • Oral Ingestion This isn't only a shelf-life question. The paper's own introduction cites earlier research showing CBD converts toward THC and related cannabinoids in artificial gastric juice — an environment in the same pH range tested here. Swallowing CBD oil exposes it, briefly, to comparable conditions inside the body.
  • Testing Blind Spots Routine potency testing usually screens for CBD and THC at a single point in time. It will not catch a product that starts clean and slowly accumulates HHC analogs, THC isomers or CBN across months on a shelf, because most labs are not set up to look for compounds that do not yet have certified reference standards.

What the Study Does Not Resolve

The authors are candid about the limits of their own data. The ethoxy-HHC, methoxy-HHC and hydroxy-HHC identifications are tentative — inferred from retention behaviour and mass spectral interpretation rather than confirmed against authentic standards, because none exist commercially for these specific compounds. The psychoactivity of the ethoxy-HHC derivatives specifically is, in the authors' own words, still controversial and not fully studied; their pharmacological profile has not been directly tested in the way delta-9 THC's has.

The experiments also used isolated CBD at fairly high purity, dissolved in pure ethanol or methanol — a simplified system, not a direct stand-in for the complex matrix of a real gummy, beverage or emulsified tincture, where other ingredients could accelerate, slow, or otherwise change these reactions. And while the pH and temperature ranges tested were chosen to be systematic, they are a controlled screen, not a simulation of any one product's actual storage history. What the study firmly establishes is that the chemistry is real and follows predictable, mechanistically explainable pathways — not whether any specific commercial CBD product on a shelf right now has crossed into psychoactive territory.

What it does put to rest is the idea that CBD is chemically inert once it leaves the plant. Given the wrong pH, it very much is not — and the compounds it becomes are not obscure novelties. They are the same THC isomers, the same CBN, and structural cousins of the same HHC that the market has spent the last few years arguing about.



Source Study: Jeong M, Lee S, Seo C, Kwon E, Rho S, Cho M, Kim MY, Lee W, Lee YS, Hong J. Chemical transformation of cannabidiol into psychotropic cannabinoids under acidic reaction conditions: Identification of transformed products by GC-MS. Journal of Food and Drug Analysis 2023, 31(1), Article 11, 165–176. doi:10.38212/2224-6614.3452 — College of Pharmacy, Kyung Hee University; Graduate School of Techno Design, Kookmin University; College of Pharmacy, Woosuk University, Republic of Korea. Received 16 August 2022; Published online 15 March 2023.
The Certified — The Grower's Connect  ·  thecertified.co.za
Posted on

THC Degradation & Cannabis Curing

THC Degradation & Cannabis Curing: What Time Actually Does to Your Cannabinoids
THC Degradation & Cannabis Curing: What Time Does to Cannabinoids
Cultivation Science · Post-Harvest

Continuing the cultivation science arc. We have covered harvest timing, AI readiness tools, and what bud rot does to your cannabinoids. This week we look at what happens after the cut — the science of cannabinoid change over time, finally mapped with 8 years of real data.

Post-Harvest Science · Cannabinoid Chemistry · 2025 Research

THC Degradation & Cannabis Curing: What Time Actually Does to Your Cannabinoids

Growers have guessed at the perfect cure for decades. A 2025 study tracked 150 cannabis samples across 8 years of storage — building the first precise model of exactly how THC degrades, CBD changes, and CBN forms over time.

The Grower's Connect  ·  2025  ·  12 min read
−99% THC remaining after 8 years — falling from 35.16% down to 0.44%
2 years The exact inflection point when CBD and CBN peak before declining
R²=0.99 Accuracy of the new model predicting storage age from cannabinoid ratios
150 Resin samples analysed — the longest cannabis storage study to date
Listen to this article THC Degradation & The Science of the Cure
Audio coming soon — replace this div with your <audio> tag when ready

Article Quick Summary: Cannabinoid Storage & Degradation

  • Rapid THC Loss: THC degradation happens fastest in the first 24 months of storage, with over 90% of the psychoactive compound breaking down by year two.
  • The 2-Year CBN Peak: As THC degrades via oxidation, it converts to CBN (Cannabinol). CBN reaches its absolute peak therapeutic concentration exactly at the two-year storage mark.
  • CBD Fluctuations: CBD levels actually rise during early storage (as CBDA decarboxylates) before slowly degrading after the two-year inflection point.
  • Yield Collapse: Storing cannabis long-term doesn't just change the chemical profile; it drastically reduces extractable yield (crude resin) by up to 87%.

Ask a grower how long they cure their cannabis, and you'll get as many answers as there are growers. Eight weeks. Six months. A year. Some swear by extended cures, claiming a smoother smoke and a heavier, more medicinal effect. Others chase the freshest possible harvest to preserve volatile terpenes. Almost none of them have hard data.

The transformation that happens inside curing cannabis — specifically THC degradation, the accumulation of CBN, and the shifting of the whole cannabinoid profile — has been one of the most poorly understood processes in cultivation. Not because it isn't important, but because studying cannabis shelf life properly requires years of patience and a very large sample set.

A team from Morocco's Forensic Sciences Institute of the Royal Gendarmerie and the University of Sidi Mohammed Ben Abdellah did exactly that. Published in Scientific Reports in 2025, their study analysed 150 cannabis resin samples seized from the Rif Mountains and stored under forensic archiving conditions for periods ranging from fresh up to eight years.

Using gas chromatography, they measured THC, CBD, and CBN concentrations at five distinct storage points — zero, two, four, six, and eight years — and built mathematical models that can predict cannabinoid content based on storage time. They can tell you, with near-certainty, exactly what time does to your weed.

Cannabis Storage Research: Why This 8-Year Study Changes Curing

Previous research on cannabinoid stability and THC degradation typically followed samples for one to four years. The authors note that an eight-year dataset of this scale is unprecedented in published literature. This matters because the behaviour of cannabinoids over time is not linear.

As the study demonstrates clearly, THC degrades rapidly in the first two years, then the rate of loss slows down. CBD and CBN rise simultaneously, peak, and then fall. The long-term endpoint of the curing process is very different from what you see at the two-year mark. Short studies can only see one part of the curve.

About the Sample Type

This study used compressed cannabis resin — hashish — rather than whole flower. Resin is produced from the exact same glandular trichomes that cover cannabis inflorescences. The cannabinoid chemistry is directly comparable to what happens in cured flower, and the degradation pathways (THC to CBN conversion) are identical. Storage conditions were dark, dry, at ambient temperatures (20–25°C) in sealed bags — conditions analogous to a well-maintained curing environment.

The Curing Timeline: What Happens to THC, CBD, and CBN Year by Year

The clearest way to understand how long to cure cannabis — and what happens if you store it too long — is to walk through the data chronologically. The researchers measured average values for each cannabinoid at each storage point. What emerges is a story that plays out in three distinct phases.

Fresh — Unstored

THC Dominates, CBD and CBN Are Minor

Fresh resin showed the highest overall extraction yield at 37.9% ± 1.45% of dry weight. THC concentration sat at 35.16% ± 3.87% — dominant and high. CBD was present at 3.92%, and CBN at a low baseline of 0.87%. This is the profile of a plant that has just been harvested: THC is fully intact, CBN formation has barely started, and CBD is present as a minor component. This is also the point at which the cannabis yields the most extract.

2 Years

The First Major Shift — THC Crashes, CBD and CBN Peak

The two-year mark sees the most dramatic single change in the entire dataset. THC falls to 2.74% — a loss of more than 90% of its initial concentration. At the same time, CBD rises to 6.71% (its highest point across any storage period) and CBN reaches 6.94% (also its absolute peak). The THC/CBN ratio, which starts extremely high in fresh material, has inverted completely. This is the crucial inflection point of cannabis storage.

4 Years

Continued THC Degradation, CBD and CBN Decline

THC continues falling to 2.24%. CBD drops back to 5.58%, and CBN slightly lowers to 6.51%. The peak of CBD and CBN observed at the two-year mark is not maintained forever — both cannabinoids begin their own slow degradation once the precursor THC has largely depleted. The profile is now dominated entirely by CBD and CBN, with THC left as a minority cannabinoid.

6 – 8 Years

Total Cannabinoid Depletion Accelerates

At six and eight years, THC levels drop to negligible amounts. In the eight-year sample, THC measured just 0.44% — less than 1.5% of its original concentration. CBD reaches its minimum at 1.76%, and CBN at 2.94%. Extraction yield reaches its floor at 5.10%, compared to 37.9% when fresh. The chemical complexity of aged cannabis accumulates as known cannabinoids break down into unidentified degradation compounds.

The Mechanism: Why THC Degrades into CBN During Storage

Understanding why weed loses potency matters as much as knowing when it happens. The researchers confirm what the biochemistry literature had already proposed, and extend it with the longest dataset yet assembled.

THC to CBN Oxidation

THC degrades primarily through oxidation. The mechanism involves the formation of intermediate hydroxylated derivatives before final conversion to CBN (Cannabinol). This process follows first-order kinetics — meaning the rate of loss is proportional to how much THC remains. Heat and oxygen exposure accelerate this conversion significantly.

Why CBD Also Rises, Then Falls

CBD's concurrent rise with CBN during the first two years is not a direct product of THC degradation. Instead, both CBD and CBN increase together during early storage because CBDA (the acid precursor) decarboxylates slowly over time to release free CBD. After two years, CBD itself begins to degrade through a slower oxidative pathway.

Extraction Yield Collapse

The extraction yield falls from 37.9% to 5.10% over eight years — an 87% reduction. The researchers point to additional mechanisms beyond cannabinoid loss: volatilisation of terpenes, adsorption of cannabinoids to packaging, and the formation of polymeric degradation compounds that are no longer soluble.

What Happens to Everything Else

GC/FID analysis measures only THC, CBD, and CBN. Aged samples accumulate a large number of unidentified peaks — cannabinoid isomers and oxidised derivatives (including Δ⁸-THC). The known cannabinoids do not account for all the mass lost from THC, which is why CBN accumulation alone cannot explain the full scale of THC disappearance.

"At two years of storage, CBD and CBN have both reached their highest concentrations — while THC has lost more than 90% of its original level. The plant's chemistry has been effectively inverted by time and oxygen alone."

Predicting Cannabinoid Degradation: Calculating THC Loss Over Time

Building predictive models was the second major objective of the study, and this is where forensic science meets grower utility. The team developed two classes of model: one that predicts cannabinoid content from storage time, and one that works in reverse — predicting how long cannabis has been stored based on its cannabinoid profile.

The researchers found that the cubic regression model outperformed all others when tracking THC, CBD, and CBN. The cubic model achieved validation R² values of 0.999 for THC, perfectly capturing the multi-phase behaviour of stored cannabis: rapid early change, a transitional period, and a slow long-term decline.

The Cubic Degradation Equations — Reading the Math

  • THC (%): = 3.30 − 0.10 × (years) + 0.055 × (years)² − 0.005 × (years)³. THC falls rapidly from the start, but the cubic term means the rate of loss slows down at higher storage durations — the curve flattens as THC approaches zero.
  • CBD (%): = 10.35 − 0.28 × (years) − 0.0157 × (years)² + 0.0007 × (years)³. CBD starts high, declines across all time points, with a steepening decline in mid-storage before flattening at the long-term tail.
  • CBN (%): = 8.72 − 0.123 × (years) − 0.024 × (years)² + 0.0005 × (years)³. CBN's curve shows a similar shape to CBD — a starting peak that declines over extended storage, with the cubic term capturing the very slow long-term degradation tail.
What This Means for Growers

If you know how long you have been curing your harvest, you can use these exact curves to estimate where your cannabinoid profile now sits. You can determine if the direction of change is still working in your favour, or if your weed has moved past the point of peak therapeutic value. The two-year inflection point — where CBD and CBN peak and then begin declining — is your ultimate reference mark.

How to Cure Cannabis: What This Means for Your Storage Strategy

The study was designed for forensic scientists, but the data speaks directly to decisions that every grower makes regarding their curing jars. Here is what the findings imply for your post-harvest cultivation practice.

Applied Implications for Curing & Storage

  • The Two-Year Mark If your goal is maximum CBN content — highly sought after for its sedative, analgesic, and anti-inflammatory properties — long-term storage up to the two-year mark is the ultimate strategy. Storing beyond two years does not accumulate more CBN; it begins to deplete it.
  • CBD and the Cure CBD rises during early storage and peaks at the two-year point. This suggests that for CBD-dominant cultivars, there is a genuine, mathematically proven benefit to extended curing far beyond the standard 4–8 week window.
  • THC and the Cure For THC-dominant cultivars, this study is unambiguous: THC degrades fast and early. Over 90% of the drop occurs within the first two years. Shorter, well-managed cures in dark, sealed, cool conditions can slow this oxidative process, but they cannot stop it entirely.
  • CBN/THC Ratio The ratio of CBN to THC is a reliable indicator of how long cannabis has been stored. Fresh material has a very low CBN/THC ratio; aged material has an inverted one. Tracking this ratio across lab tests during curing is incredibly informative.
  • Strategic Medicine Deliberate long-term storage of cannabis can be used strategically to enhance therapeutic value by allowing THC to fall while CBD and CBN accumulate. For medicinal producers targeting non-psychoactive profiles for sleep and pain, a two-year cure is not spoilage — it is a precise production method.
The Extraction Yield Problem

The 87% drop in extraction yield over eight years is a stark reminder that cannabinoid percentages tell only part of the story. If you are making extracts or concentrates from long-stored flower, the cannabinoid ratios may look favourable on paper (high CBN) — but the total mass of extract you can recover from a given weight of material drops substantially with time.

What this study establishes, firmly and for the first time across an eight-year arc, is the exact shape of the cannabinoid degradation curve. The days of guessing what time does to your cannabinoids are officially over.

Frequently Asked Questions About Cannabis Storage & Degradation

Does weed lose potency over time?

Yes. Cannabis loses potency (specifically THC) over time through a process called oxidation. Research shows that THC degrades rapidly within the first 24 months of storage at ambient temperatures, potentially losing up to 90% of its original concentration if not stored in optimal, airtight, cold conditions.

Does old weed turn into CBN?

Yes. As THC is exposed to oxygen and ambient heat over time, it degrades and converts directly into Cannabinol (CBN). CBN is a mildly psychoactive cannabinoid known for its heavy, sedative properties. The highest concentration of CBN in stored cannabis typically occurs around the two-year mark.

How long should you cure cannabis for the best results?

The ideal curing time depends on your goals. For maximum THC preservation and fresh terpene profiles, a standard 4 to 8-week cure in airtight jars (burped regularly) is optimal. However, if you are looking to create a highly sedative, CBN-rich medicinal product, curing and storing the cannabis for up to two years will maximize CBN and CBD levels while lowering THC.



Source Study: Fettoukh N, Fadil M, Stambouli H, EL Bouri A, Bouyoun T, Annemer S, Boukhaled A, Farah A. Chemometric and predictive modeling of long term cannabinoid transformation in stored Cannabis sativa resin. Scientific Reports 2025, 15, 33827. doi:10.1038/s41598-025-03888-7 — Forensic Sciences Institute of Royal Gendarmerie, Rabat, Morocco; Laboratory of Applied Organic Chemistry, University Sidi Mohammed Ben Abdellah, Fez, Morocco. Received 1 March 2025; Published online 30 September 2025.
The Certified — The Grower's Connect  ·  thecertified.co.za
Posted on

Cannabis Bud Rot: The Rot You Don’t See Until It’s Too Late

cannabis bud rot
Cannabis Bud Rot (Botrytis): What Grey Mould Does to Trichomes & Cannabinoids
Cultivation Science · Disease

Continuing our cultivation science arc. The last two weeks explored how to read harvest readiness. This week we look at what happens when a fungal pathogen gets there first — and what it does to the trichomes and cannabinoids before you even notice it.

Cannabis Pathology · Trichome Science · 2026 Research

Cannabis Bud Rot: The Rot You Don't See Until It's Too Late

Bud rot doesn't just destroy yield. A 2026 preprint from India documents what Botrytis cinerea actually does inside your flower — collapsing trichome structure, wiping out CBD, and rewriting the plant's cannabinoid chemistry from the inside out.

The Grower's Connect  ·  2026  ·  11 min read
−91% CBD collapse in field-infected plants (1.87% to 0.16%)
+117% THC increase in infected plants (1.04% to 2.25%)
20°C / 94%RH The peak trigger conditions for Botrytis spore production
7 days Time required for complete bud colonisation in high humidity
Listen to this article The Rot You Don't See Until It's Too Late
Audio coming soon — replace this div with your <audio> tag when ready

Article Quick Summary: What Bud Rot Does

  • Structural Damage: Botrytis cinerea physically crushes and destroys the capitate-stalked trichomes where cannabis stores its resin.
  • Cannabinoid Shift: Infection causes a catastrophic drop in CBD levels (up to 91% reduction) while simultaneously doubling THC levels, creating massive compliance risks.
  • Terpene Loss: Essential therapeutic terpenes, notably Myrcene and Limonene, see reductions of up to 79% in infected buds.
  • Hidden Infection: Spores colonize the deep vascular tissue of the bud days before grey mould becomes visible on the surface or during the curing process.

Most cannabis growers who have dealt with bud rot (Botrytis cinerea) describe the same devastating experience. You're a week or two from harvest. The flowers look dense, healthy, and frosted with trichomes. Then you find it — a patch of grey-brown fuzz buried inside a cola, or a single bract that crumbles when you touch it. By the time grey mould is visible on the surface, it has already been inside the flower for days, possibly weeks. The damage is done.

What that damage actually looks like — chemically, structurally, at the level of the trichomes themselves — has never been fully documented. Growers have known for years that infected buds smell wrong, smoke harsh, and test lower for potency. But the precise mechanism, and the specific changes to the cannabinoid and terpene profile that infection causes, had not been studied in a controlled scientific setting. Until now.

A preprint posted to Research Square in February 2026 by researchers at CSIR-Central Institute of Medicinal and Aromatic Plants in Lucknow, India, reports the first characterisation of Botrytis cinerea infecting cannabis. More importantly, it provides the first direct measurement of what that infection does to trichome structure, cannabinoid content, and terpene profiles. The findings are unsettling, and directly relevant to anyone growing CBD-dominant or medicinal cannabis.

What is Botrytis Cinerea (Bud Rot) in Cannabis?

Botrytis cinerea is the causal agent of grey mould, universally known to cultivators as cannabis bud rot. It is a necrotrophic fungal pathogen, meaning it actively kills the host tissue it colonises rather than living within it subtly. Ranked the second most economically damaging fungal pathogen globally, it attacks over 200 plant species. Cannabis is not a special case; it is simply another highly vulnerable host.

The pathogen enters cannabis inflorescences primarily through airborne conidia — microscopic spores that are always present in the environment, whether in outdoor field conditions, indoor grow tents, greenhouses, or post-harvest drying spaces. What makes cannabis particularly susceptible is the nature of late-stage flowers: dense, moisture-retaining, and covered in glandular trichomes that the fungus exploits as entry points and nutrient sources.

Why the Curing Jar Is Not Safe

Botrytis spores persist in harvested and drying flowers. The curing environment — enclosed, slightly humid, and warm — provides the exact conditions needed to reactivate latent infections. Growers who find rot in the jar are not seeing a new contamination event; they are witnessing the final stage of an infection that began invisibly weeks earlier in the grow room.

What Causes Bud Rot? The Ideal Conditions for Botrytis Spores

To effectively prevent bud rot, cultivators need to understand environmental triggers. The Indian research team mapped the exact environmental conditions under which B. cinerea produces the most spores on cannabis inflorescences. This matters because spore load drives infection pressure — the more conidia in the air, the faster an outbreak spreads through your canopy.

Environmental Triggers for Grey Mould

  • Peak Danger Zone: Maximum spore production occurred at 20°C combined with 94% relative humidity (RH). This is the exact microclimate growers must avoid during late flower.
  • Humidity Dominates: Peak conidial counts at 94% RH reached 12.30 × 10⁶ conidia per gram — roughly five times the count observed at 60% RH. Humidity is the dominant variable.
  • Temperature Ranges: The optimal temperature range for the fungus is 15–20°C. Hot, dry conditions (30°C) suppress the pathogen, which is why bud rot is predominantly an autumn or late-season problem.
  • Cold Protection: At 10°C, essentially no spores were produced. Cold curing environments (below 15°C) with humidity below 60% are genuinely protective — confirming popular cultivator wisdom.
  • Speed of Infection: Under high humidity, complete bud colonisation occurred within just seven days of inoculation.

The practical takeaway: if your late-flower environment sits between 15°C and 25°C with a relative humidity above 85%, you are running conditions that maximise Botrytis infection success. The dense, tightly packed colas that yield the most weight are the exact structures that trap moisture and create these dangerous micro-climates.

Trichome Damage: How Botrytis Destroys Cannabis Resin

This is where the research breaks genuinely new ground. Using scanning electron microscopy, the team visualised the interaction between B. cinerea and the trichome structures of infected cannabis tissue. What they found describes a systematic dismantling of the very biological factories responsible for cannabinoid and terpene production.

Cannabis flowers carry three types of trichomes, but the capitate-stalked trichomes — the large, mushroom-shaped glands that produce the bulk of the plant's resin — were the most severely affected. Under the electron microscope, infected tissue showed:

Surface Colonisation

Extensive mycelial growth blankets the bud surface, with spore-bearing stalks growing directly from the bract tissue. The fungal mass physically displaces and crushes delicate trichomes.

Deep Vascular Invasion

The pathogen is not confined to the surface. Mycelial filaments penetrate deep into the central vascular core (xylem and phloem). This is a systemic tissue infection, not mere surface mould.

Trichome Deformation

Glandular trichomes are visibly disrupted and trapped within mycelium. The characteristic round secretory heads — which contain the valuable oils — are completely collapsed or missing.

Density Reduction

Trichome density on infected bract tissue is markedly lower than on healthy tissue. Fungal colonisation actively reduces the number of functional trichomes left on the plant.

The researchers propose a two-fold mechanism of destruction: direct physical crushing of trichomes by fungal growth, and indirect disruption of biosynthesis pathways. The plant essentially reprograms its own chemistry in a failed attempt to fight off the infection.

"The pathogen colonises the very factory that produces the plant's most valuable compounds — and the disruption is not subtle. It is a comprehensive dismantling of trichome integrity."

Cannabinoid Changes: Bud Rot Drops CBD and Increases THC

The High-Performance Liquid Chromatography (HPLC) chemical analysis is where the data becomes alarming for anyone producing medicinal hemp or CBD-dominant cannabis. The numbers reveal a dramatic, consistent chemical transformation inside the rotting bud.

Chemical Profile Shifts (Infected vs. Healthy)

  • Total CBD (Field): Crashed from 1.87% in healthy plants to 0.16% in infected plants — a devastating 91% reduction.
  • Total CBD (Greenhouse): Collapsed from 1.41% to just 0.03% — a 98% reduction. Greenhouse infections proved catastrophically damaging to CBD.
  • Total THC (Field): Increased from 1.03% in healthy plants up to 2.25% in infected plants — more than doubling the psychoactive compound.
  • Total THC (Greenhouse): Rose from 0.82% to 1.29% in infected plants. This directional shift (CBD down, THC up) was entirely consistent.

This directional shift is not a coincidence. Both CBD and THC share the same biosynthetic precursor pathway (CBGA) within the glandular trichomes. The researchers suggest the fungal infection interferes with the enzymatic steps controlling this pathway, driven by oxidative stress and the pathogen's toxic secondary metabolites (botrydial and botcinic acid).

The Compliance Risk for Hemp Growers

For commercial hemp cultivators, this finding is a major compliance risk. A CBD-dominant plant running at 1.87% CBD and 1.04% THC in healthy tissue shifts to 0.16% CBD and 2.25% THC under infection. This creates potentially illegal, "hot" non-compliant flower, destroyed crop value, and regulatory headaches — all caused by an invisible fungus.

Terpene Loss: How Grey Mould Destroys Cannabis Aromas

Gas Chromatography (GC-MS) analysis completes the picture of what cannabis bud rot truly costs. Measuring thirteen significant terpene compounds, researchers confirmed that the loss of structural trichomes directly correlates to a massive loss of therapeutic aromas.

Terpene Destruction by Botrytis

  • Myrcene: Fell from 5.78% to 1.20% in infected plants — a 79% reduction. Myrcene is critical for the "entourage effect" and anti-inflammatory properties.
  • Limonene: Dropped precipitously from 37.07% to 4.46% in greenhouse-infected plants, the largest absolute reduction of any measured compound.
  • β-Caryophyllene: Reduced from 18.54% to 13.22%. This sesquiterpene showed slight resilience but still suffered meaningful losses.

Non-infected plants presented a classic therapeutic profile: high Limonene, significant Myrcene, and strong β-Caryophyllene. Infected plants presented a distorted, hollowed-out version of this profile, stripping the flower of its medicinal value and bag appeal.

How to Prevent and Manage Cannabis Bud Rot

While this study focused on pathology, the data provides a clear roadmap for cultivators looking to prevent bud rot and protect their canopy.

Applied Cultivation Strategies

  • VPD & Humidity Control The danger zone is 15–20°C with RH above 90%. Keep your late-flower relative humidity strictly below 55% to suppress the pathogen's reproductive capacity. A single night of heavy condensation can trigger an outbreak.
  • Airflow Architecture Botrytis disperses via airborne spores. Stagnant air pockets inside dense, tightly formed colas create high-humidity micro-environments. Defoliation and aggressive under-canopy airflow are non-negotiable.
  • Early Scouting By the time you see the grey fuzz, the fungus has already penetrated the vascular tissue. Look for early symptoms: a single yellowing sugar leaf, a dark/soft bract, or an off-putting smell from an otherwise healthy cola.
  • Accelerate Harvest Because infection rapidly destroys CBD and alters THC, allowing an infected crop to finish its cycle compounds the damage. If an outbreak cannot be contained, harvesting early is chemically supported to save remaining cannabinoids.
  • Post-Harvest Hygiene Dry your cannabis in environments below 15°C and under 55% RH. Inspect curing jars daily during the first week. Curing at 60%+ RH in warm rooms will rapidly accelerate latent Botrytis spores.

Frequently Asked Questions About Cannabis Bud Rot

Can you smoke weed with bud rot?

No. Smoking cannabis infected with Botrytis cinerea (bud rot) is highly dangerous. The mould spores can cause severe respiratory infections, allergic reactions, and potentially introduce harmful mycotoxins into your lungs. Any infected plant material should be carefully bagged and discarded.

Can you save buds that have bud rot?

You cannot "cure" or save a bud once it has begun rotting. The visible grey mould is just the fruiting body; the mycelial network has already invaded deep into the vascular tissue of the flower. You must carefully cut away the infected cola, plus at least two inches of seemingly healthy tissue below it, to stop the spread.

Does bud rot spread while drying or in the curing jar?

Yes. Botrytis spores remain active after harvest. If your drying room humidity spikes above 60%, or if buds are placed into curing jars while still too wet, the latent mould spores will germinate and destroy the harvest inside the jar.


Cannabis Research Coverage — The Grower's Connect


Source Study: Yadav SS, Aftab N, Kumar B. Botrytis cinerea infection modulates trichome development and secondary metabolite biosynthesis in Cannabis sativa. Preprint posted February 6, 2026. doi:10.21203/rs.3.rs-8682864/v1 — CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India. This article is a preprint and has not yet completed peer review.
The Certified — The Grower's Connect  ·  thecertified.co.za
Posted on

Your Smartphone Can Now See What Growers Have Been Guessing At

Your Smartphone Can Now See What Growers Have Been Guessing At
Your Smartphone Can Now See What Growers Have Been Guessing At — AI Harvest Readiness | The Certified
Cultivation Science · Technology

Continuing our cultivation science arc. Last week we asked when the plant is ready — this week, researchers from Ben-Gurion University ask a more ambitious question: can a smartphone and a trained AI model answer that question better than the human eye?

Cultivation Science · AI · Computer Vision · Research 2026

Your Smartphone Can Now See What Growers Have Been Guessing At

A 2026 study from Ben-Gurion University built an AI pipeline that detects, classifies, and correlates trichomes and stigmas with HPLC-measured cannabinoid peaks — using nothing more than a consumer smartphone and a macro lens. Results were consistent across two separate experiments.

The Grower's Connect  ·  2026  ·  12 min read
98.6% trichome classification accuracy — clear, milky, or amber
14,000+ images collected across two greenhouse experiments
2 consistent experiments confirming the stigma colour signal
~55 DAF the green-to-orange stigma crossover point — aligned with cannabinoid peak
Listen to this article Your Smartphone Can Now See What Growers Have Been Guessing At
Audio coming soon — replace this div with your <audio> tag when ready

Every grower has done it. You hold the flower up to a loupe, tilt it toward the light, and try to decide how many trichomes have turned amber. Is it thirty percent? Fifty? The loupe doesn't have a percentage counter. Your eye makes its best guess, your experience fills in the gaps, and you make a call. The same thing happens with stigmas — you eyeball the ratio of orange to green and trust your read.

This is not a criticism of the method. It has worked for decades, for good reason. Trichomes and stigmas really do change colour as the plant matures. The problem is reproducibility. Two experienced growers looking at the same plant can reach different conclusions. The same grower can reach different conclusions on different days. What the field has been missing is an objective, automated system that can extract a precise measurement from an image — and then tell you what that measurement actually means for cannabinoid content.

A study published in Agriculture in February 2026 by researchers at Ben-Gurion University of the Negev, working in collaboration with RCK Science-Based Cannabis Genetics, built exactly that. Their system uses a consumer smartphone fitted with a clip-on macro lens, a multi-stage AI pipeline running Faster R-CNN for trichome detection and YOLOv8 for both trichome classification and stigma segmentation, and a correlation framework that links visual measurements to HPLC-verified cannabinoid data. The study ran two separate experiments across two growing seasons, and the key signals held in both.

Why Two Separate Tools Were Needed

The researchers built a dual-path pipeline because trichomes and stigmas are different problems. Trichomes are small — the tiny glandular structures that produce cannabinoids — and they cluster densely on the flower surface. Stigmas are the larger thread-like structures that receive pollen during fertilisation and visibly shift from green to orange as the plant moves through its flowering period. Each indicator requires its own detection and analysis strategy.

Trichome Path

A fine-tuned Faster R-CNN model detects individual trichomes in high-resolution image patches. A YOLOv8 X-Large classifier then assigns each detected trichome to one of three classes: clear (immature), milky (peak biosynthesis), or amber (post-peak). Classification accuracy across both tasks reached 98.6%.

Stigma Path

A YOLOv8-small segmentation model isolates individual stigmas from the flower image. A pixel-level nearest-neighbour classifier then assigns each pixel within the stigma to either green (immature) or orange (mature). The ratio of orange to green pixels gives a continuous maturity score for each stigma and flower.

Both paths aggregate their outputs at the flower level — so the system doesn't just tell you about one trichome or one stigma, but about the overall profile of the whole flower. Those flower-level statistics were then correlated with HPLC-measured cannabinoid concentrations taken on the same measurement days, giving the team a ground truth to validate against.

The Imaging Setup — What the Smartphone Actually Did

One of the more remarkable aspects of this research is how deliberately low-tech the imaging hardware is. The team used an iPhone 14 Pro and an iPhone 12, each fitted with a Moment Macro Lens M-series clip-on attachment. The iPhone 14 Pro achieved an effective magnification of around thirty times; the iPhone 12 reached twenty times. Both were used with the CameraPixels app, which handled auto-exposure, ISO, and focus settings.

Why This Matters for Growers

The deliberate choice of consumer hardware was not a compromise — it was a design goal. The researchers wanted a system that any cultivator could use without investing in laboratory microscopy or specialised imaging equipment. A clip-on macro lens for a modern smartphone costs a fraction of a professional microscope. If the AI can extract reliable maturity signals from this level of hardware, the barrier to adoption drops dramatically.

Images were captured both inside a working greenhouse — with natural light variation — and in a controlled laboratory environment after harvest, with an adjustable LED lamp. The CameraPixels app's auto-exposure functionality handled the lighting differences, giving the model a diverse and realistic training set rather than one calibrated to ideal lab conditions.

Each high-resolution image was divided into non-overlapping 512 × 512 pixel patches. A pre-processing sharpness filter — based on Canny edge detection — then discarded blurry or out-of-focus patches before passing the remaining regions to the AI models. This filtering step proved critical: one of the key findings from the failure analysis was that image quality, not model capacity, was the primary source of missed detections.

What the AI Actually Detected — and How Well

Trichome detection is the harder of the two problems. The structures are small, they cluster together, and the distinction between a clear and a milky trichome is genuinely subtle. The team tested a wide range of state-of-the-art object detection architectures and found that their two-stage pipeline — Faster R-CNN for detection, then a separate YOLOv8 classifier for the maturity class — outperformed all single-stage alternatives.

Pipeline Performance — Key Metrics

  • Trichome detection with Faster R-CNN (ResNet-50 C4): Precision 0.815, Recall 0.802 — the best balance among all tested architectures at an IoU threshold of 0.5.
  • Trichome classification with YOLOv8 X-Large: overall accuracy 98.6%, with weighted precision and recall both exceeding 0.98 across the three classes (clear, milky, amber).
  • The full two-stage pipeline achieved Precision 0.803 and Recall 0.790, a substantial improvement over the best single-stage model — YOLOv9 — which reached only 0.582 precision and 0.620 recall.
  • Stigma segmentation with YOLOv8-small: AP50 of 52.2%. While moderate in absolute terms, this was sufficient to extract meaningful stigma regions for the colour ratio analysis.
  • Dataset size: over 14,000 images collected across multiple sessions in two experiments, spanning different growing seasons and greenhouse conditions.

The gap between the two-stage pipeline and the single-stage models is worth understanding. The detection stage specialises in finding trichomes — just localising them. The classification stage then focuses entirely on reading the colour of each detected trichome. By separating these two tasks, the system avoids the compounding of errors that happens when a single model tries to do both at once. This is particularly important for the subtle distinction between clear and milky trichomes, which look almost identical to the human eye but carry opposite implications for harvest timing.

"The distinction between milky and clear trichomes is much more difficult than the distinction between green and orange stigmas — and the data shows it. Stigmas outperformed trichomes as harvest predictors, partly because they are larger and easier to image accurately with low-end equipment."

Experiment One — What the Correlations Showed

The first experiment ran across six cannabis cultivars during a spring growing season, imaging flowers at seven time points from day 51 to day 79 after flowering initiation. HPLC measurements were taken on the same days, providing a cannabinoid profile to correlate against the AI-derived visual metrics.

The trichome results were mixed. Milky trichomes showed moderate positive correlations with total cannabinoid levels in some cultivars — supporting the biological expectation that milky trichomes reflect the active biosynthesis phase. Clear trichomes generally showed negative correlations, consistent with immature tissue. But amber trichomes were inconsistent across genotypes: in some cultivars, rising amber ratios accompanied rising cannabinoid levels; in others, they did not.

The Amber Trichome Paradox

Growers are commonly advised to watch for amber trichomes as the harvest signal — yet the data from Experiment 1 showed that amber trichome ratios were the weakest predictor of cannabinoid peak, with RMSE values of 8.68 days compared to 4.54 for orange stigmas. In one cultivar (616), amber trichomes actually showed a negative correlation with Total THC (r = −0.41), meaning rising amber ratios coincided with falling THC. The amber signal is real, but it does not translate cleanly into cannabinoid data across all genotypes.

Stigma colour told a more consistent story. Across all six cultivars, green stigma ratios declined while orange ratios rose over time. The point where those two curves crossed — the visual transition from green-dominant to orange-dominant — closely coincided with the peak in total cannabinoid concentration in most cases. This was especially clear in four of the six cultivars (805-12, 1416-3, 611, and 616), where the crossover nearly aligned with the cannabinoid maximum.

When the team formalised this into a harvest day prediction model — using the first day where the orange stigma ratio exceeded 40% as the threshold — they found it outperformed both milky and amber trichome predictors. Excluding four outlier plants affected by imaging quality issues, the orange stigma predictor achieved an RMSE of 1.83 days for total cannabinoids, compared to 2.57 days for simply predicting the average flowering day.

Experiment Two — Confirming the Signal

The second experiment was conducted during winter 2024–25 using three of the cultivars from Experiment 1, with an improved imaging and annotation protocol designed to address the consistency issues identified in the first round. The results were notably cleaner.

What Experiment Two Confirmed

  • Stigma crossover The green-to-orange stigma transition occurred consistently around 55–60 Days After Flowering across all three cultivars tested, and this inflection point closely coincided with the peak of total cannabinoid levels in each case.
  • Milky trichomes The positive relationship between milky trichome ratios and total cannabinoid concentration became clearer and more consistent in Experiment 2 compared to the mixed results of Experiment 1, supporting the interpretation that milky trichomes reflect the active biosynthesis phase.
  • Amber trichomes Rising amber trichome ratios consistently appeared after the cannabinoid peak — not before or during it. In all three cultivars, amber ratios increased steeply in the late flowering period while THC concentrations declined, reinforcing their role as a post-peak indicator rather than a peak signal.
  • Seasonal consistency The pattern held across two different growing seasons — spring and winter — despite the fact that seasonal differences in light, temperature, and growth rate can significantly influence cannabis development. This consistency strengthens confidence in the underlying biological signal.

The improved sampling protocol in Experiment 2 mattered. Many of the outlier predictions in Experiment 1 were traced back to image quality problems — blurry frames, shallow depth of field, or imaging angle variability that caused the same plant on the same day to yield very different trichome counts depending on how the camera was positioned. When these acquisition variables were better controlled, the biological signal became more consistent.

What the Results Actually Mean for Harvest Decisions

The study is clear that this is a proof-of-concept. Six cultivars in one greenhouse, two smartphone models, and a dataset of thirty plants does not produce a model ready for commercial deployment. The authors say so explicitly. But the directional findings are robust enough to draw practical conclusions.

Reading the Evidence — What Growers Can Take Away

  • Stigma colour is the more reliable visual indicator of peak cannabinoid concentration — more reliable than either milky or amber trichomes — partly because stigmas are larger and easier to image accurately with consumer-grade equipment.
  • The crossover point — where orange stigmas begin to outnumber green — is a more actionable signal than any fixed percentage of trichome colour. In both experiments, this crossover occurred near peak cannabinoid concentration across most cultivars.
  • Amber trichomes are a post-peak signal in most cases. Waiting until trichomes are predominantly amber may mean the plant has already passed its cannabinoid maximum. This directly challenges the most commonly cited version of the amber rule.
  • Milky trichomes are the more relevant trichome signal for cannabinoid peak — but they are harder to classify reliably from smartphone images because the visual distinction between clear and milky is subtle at macro scale.
  • Image quality is the limiting factor, not model capacity. Blurry or out-of-focus frames produce unreliable trichome counts. Consistent focus, steady capture technique, and morning imaging (when greenhouse light is stable) significantly improve output quality.

What Is Still Missing — and What Comes Next

The study's limitations are worth naming clearly. The stigma segmentation model was trained on only 115 images — a small dataset that constrains how well it generalises to different cultivars, lighting conditions, and camera hardware. The correlation experiments covered six cultivars in Experiment 1 and three in Experiment 2, which is not enough to build genotype-independent maturity prediction models.

The trichome-to-cannabinoid correlations were also inconsistent across genotypes in Experiment 1, which the authors attribute to both biological variability and sampling limitations. Some cultivars showed strong patterns; others showed weaker or inverted ones. This genotype-dependency is a known challenge in cannabis phenotyping and is not specific to this study — it was also a finding in last week's Tran et al. paper on stigma colour staging across 25 genotypes.

The Consistent Finding Across Both Papers

Two independent research groups, different methodologies, different scales of experiment — and both converged on the same conclusion: the green-to-orange stigma transition is a more reliable visual indicator of peak cannabinoid concentration than trichome colour alone. Last week's Tran et al. study established this across 25 genotypes using manual staging. This week's Lorberboym et al. study automated the measurement and confirmed the same signal across two growing seasons using AI. The convergence is significant.

The authors identify the path forward: larger datasets across more cultivars and environments, better image acquisition protocols with automated quality filtering built into the capture step, and direct integration testing in live greenhouse workflows. They also note the possibility of combining the visual pipeline with additional inputs — days after flowering, temperature data, cultivar-specific calibration — to build a multi-feature model once sufficient training data exists.

The long-term vision is a field-ready tool that any cultivator can use on a smartphone: point it at a flower, capture a sharp macro image, and receive an AI-derived maturity score alongside a harvest recommendation window. That tool doesn't exist yet at commercial scale. But this paper shows it is not a distant possibility. The biology is consistent. The AI can read it. The question now is how many more flowers, cultivars, and seasons of data it takes to make the system robust enough to trust.



Source Study: Lorberboym E, Lazare S, Golshmid P, Shani G. Estimating Cannabis Flower Maturity in Greenhouse Conditions Using Computer Vision. Agriculture 2026, 16, 460. doi:10.3390/agriculture16040460 — Faculty of Computer and Information Science, Ben-Gurion University of the Negev, Beer-Sheva, Israel; RCK Science-Based Cannabis Genetics, Kibbutz Ruhama, Israel. Published 16 February 2026. Funded in part by the Israeli Innovation Authority, grant 8114581.
The Certified — The Grower's Connect  ·  thecertified.co.za